<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "http://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id specific-use="scielo-v3" pub-id-type="publisher-id">5S6Lt6c5WSmFq43wT7GM3Zn</article-id>
      <article-id specific-use="scielo-v2" pub-id-type="publisher-id">S0066-782X2020000900229</article-id>
      <article-id pub-id-type="publisher-id">abc.20180346</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20180346</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo Original</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Revasculariza&#231;&#227;o Completa <italic>Versus</italic> Tratamento da Art&#233;ria Culpada no Infarto com Supradesnivelamento do Segmento ST: Registro Multic&#234;ntrico</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cadore</surname>
            <given-names>Julia Cremona</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Furtado</surname>
            <given-names>Mariana Vargas</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tumelero</surname>
            <given-names>Rog&#233;rio Tadeu</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tognon</surname>
            <given-names>Alexandre Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Krepsky</surname>
            <given-names>Ana Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cadore</surname>
            <given-names>Denis</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-0812-920X</contrib-id>
          <name>
            <surname>Ruschel</surname>
            <given-names>Karen Brasil</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bedin</surname>
            <given-names>Julia Caldas</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Conte</surname>
            <given-names>Thais</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Polanczyk</surname>
            <given-names>Carisi Anne</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
        <institution content-type="orgdiv1">PPG Ci&#234;ncias Cardiovasculares: Cardiologia</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal do Rio Grande do Sul - PPG Ci&#234;ncias Cardiovasculares: Cardiologia, Porto Alegre, RS - Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">Hospital de Cl&#237;nicas de Porto Alegre</institution>
        <institution content-type="orgdiv1">Instituto de Avalia&#231;&#227;o de Tecnologia em Sa&#250;de</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital de Cl&#237;nicas de Porto Alegre - Instituto de Avalia&#231;&#227;o de Tecnologia em Sa&#250;de, Porto Alegre, RS - Brasil</institution>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <institution content-type="orgname">Associa&#231;&#227;o Hospitalar Beneficente S&#227;o Vicente de Paulo</institution>
        <addr-line>
          <named-content content-type="city">Passo Fundo</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Associa&#231;&#227;o Hospitalar Beneficente S&#227;o Vicente de Paulo, Passo Fundo, RS - Brasil</institution>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <institution content-type="orgname">Universidade Federal do Rio Grande do Sul</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal do Rio Grande do Sul - Faculdade de Medicina, Porto Alegre, RS - Brasil</institution>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <institution content-type="orgname">Hospital de Cl&#237;nicas de Porto Alegre</institution>
        <addr-line>
          <named-content content-type="city">Porto Alegre</named-content>
          <named-content content-type="state">RS</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital de Cl&#237;nicas de Porto Alegre, Porto Alegre, RS &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Carisi Anne Polanczyk &#8226; Hospital de Cl&#237;nicas de Porto Alegre - Instituto de Avalia&#231;&#227;o de Tecnologia em Sa&#250;de - Rua Ramiro Barcelos, 2350. CEP 90035-903, Porto Alegre, RS &#8211; Brasil E-mail: <email>carisi.anne@gmail.com</email> </corresp>
        <fn fn-type="con">
          <p>Contribui&#231;&#227;o dos Autores</p>
          <p>Concep&#231;&#227;o e desenho da pesquisa: Cadore JC, Furtado MV, Tumelero R, Tognon A, Krepsky AM, Cadore D, Polanczyk CA; Obten&#231;&#227;o de dados: Cadore JC, Tumelero R, Krepsky AM, Cadore D, Bedin JC, Conte T; An&#225;lise e Polanczyk CA interpreta&#231;&#227;o dos dados: Cadore JC, Furtado MV, Tognon A, Ruschel KB; An&#225;lise estat&#237;stica: Cadore JC, Tognon A, Polanczyk CA; Reda&#231;&#227;o do manuscrito: Cadore JC, Tognon A, Cadore D; Revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante: Furtado MV, Ruschel KB, Polanczyk CA.</p>
        </fn>
        <fn fn-type="conflict">
          <p>Potencial Conflito de Interesses</p>
          <p>Os autores declaram n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>28</day>
        <month>08</month>
        <year>2020</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>08</month>
        <year>2020</year>
      </pub-date>
      <volume>115</volume>
      <issue>2</issue>
      <fpage>229</fpage>
      <lpage>237</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>11</month>
          <year>2018</year>
        </date>
        <date date-type="rev-recd">
          <day>14</day>
          <month>06</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>08</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <abstract>
        <title>Resumo</title>
        <sec>
          <title>Fundamento</title>
          <p> S&#227;o restritos os dados sobre o manejo e o progn&#243;stico dos pacientes com infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST (IAMCSST) com acometimento multiarterial no Brasil, o que mostra a necessidade de investigar as estrat&#233;gias de revasculariza&#231;&#227;o dispon&#237;veis.</p>
        </sec>
        <sec>
          <title>Objetivo</title>
          <p> Avaliar os desfechos relacionados &#224; revasculariza&#231;&#227;o completa em compara&#231;&#227;o com o tratamento da art&#233;ria culpada em pacientes multiarteriais com IAMCSST.</p>
        </sec>
        <sec>
          <title>M&#233;todos</title>
          <p> Foi realizada um estudo de coorte prospectiva em dois centros de hemodin&#226;mica do Sul do Brasil, com seguimento de 1 ano ap&#243;s a interven&#231;&#227;o &#237;ndice. O desfecho prim&#225;rio foi composto de &#243;bito cardiovascular, reinfarto ou angina recorrente e secund&#225;rios acidente vascular encef&#225;lico, parada cardiorrespirat&#243;ria n&#227;o fatal, sangramento maior ou necessidade de reinterven&#231;&#227;o. A probabilidade de ocorr&#234;ncia de desfechos foi comparada entre os grupos atrav&#233;s de regress&#227;o log&#237;stica bin&#225;ria. Considerou-se como estatisticamente significativo o valor de probabilidade &lt; 0,05.</p>
        </sec>
        <sec>
          <title>Resultados</title>
          <p> Participaram 85 pacientes, com m&#233;dia de idade de 62&#177;12 anos, sendo 61 (71,8%) do sexo masculino. Cinquenta e oito (68,2%) pacientes receberam a estrat&#233;gia de revasculariza&#231;&#227;o completa e 27 (31,8%), a de revasculariza&#231;&#227;o incompleta. A chance de ocorr&#234;ncia tanto do desfecho prim&#225;rio quanto do secund&#225;rio foi significativamente maior entre os indiv&#237;duos tratados com revasculariza&#231;&#227;o incompleta quando comparados com os tratados com estrat&#233;gia completa [raz&#227;o de chances (OR) 5,1, intervalo de confian&#231;a de 95% (IC95%) 1,6-16,1 vs. OR 5,2, IC95% 1,2-22,9, respectivamente], assim como os &#243;bitos cardiovasculares (OR 6,4, IC95% 1,2-35,3).</p>
        </sec>
        <sec>
          <title>Conclus&#227;o</title>
          <p> Dados deste registro regional, de dois centros do Sul do Brasil, demonstram que a estrat&#233;gia de revasculariza&#231;&#227;o completa esteve associada &#224; redu&#231;&#227;o significativa dos desfechos prim&#225;rio e secund&#225;rio no seguimento de 1 ano quando comparada &#224; estrat&#233;gia de revasculariza&#231;&#227;o incompleta. (Arq Bras Cardiol. 2020; 115(2):229-237)</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <kwd>Infarto do Mioc&#225;rdio com Supradesn&#237;vel do Segmento ST/mortalidade</kwd>
        <kwd>Estudos de Coortes</kwd>
        <kwd>Hemodin&#226;mica</kwd>
        <kwd>Registros de &#211;bitos</kwd>
        <kwd>Angina Pectoris</kwd>
        <kwd>Acidente Vascular Cerebral</kwd>
        <kwd>Parada Card&#237;aca</kwd>
        <kwd>Interven&#231;&#227;o Coron&#225;ria Percut&#226;nea</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="8"/>
        <equation-count count="0"/>
        <ref-count count="24"/>
        <page-count count="9"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>O infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST (IAMCSST) constitui um problema de extrema relev&#226;ncia em sa&#250;de p&#250;blica,<sup><xref ref-type="bibr" rid="B1">1</xref></sup> apresentando alta taxa de mortalidade caso n&#227;o seja tratado adequadamente.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Aproximadamente 50% dos pacientes apresentam doen&#231;a arterial coronariana (DAC) multiarterial,<sup><xref ref-type="bibr" rid="B3">3</xref> - <xref ref-type="bibr" rid="B4">4</xref></sup> sendo o progn&#243;stico ainda mais desfavor&#225;vel.<sup><xref ref-type="bibr" rid="B5">5</xref></sup></p>
      <p>As op&#231;&#245;es terap&#234;uticas para esse grupo mais complexo incluem interven&#231;&#227;o coronariana percut&#226;nea (ICP) prim&#225;ria na art&#233;ria culpada pelo infarto (ACI) e ICP nas demais estenoses somente na presen&#231;a de isquemia espont&#226;nea ou achados de risco em testes n&#227;o invasivos (revasculariza&#231;&#227;o incompleta &#8211; RI); ICP multiarterial no momento da ICP prim&#225;ria (revasculariza&#231;&#227;o completa &#8211; RC); ICP prim&#225;ria na ACI e tratamento estadiado das demais estenoses (RC estadiada). Estudos iniciais demonstraram resultados conflitantes.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> O estudo PRAMI ( <italic>Preventive Angioplasty in Acute Myocardial Infarction</italic> ), no entanto, trouxe uma mudan&#231;a nesse paradigma, na medida em que demonstrou o benef&#237;cio da ICP multiarterial comparada com a ICP prim&#225;ria apenas da ACI.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Outros ensaios cl&#237;nicos refor&#231;aram a hip&#243;tese de que uma estrat&#233;gia de RC poderia ser ben&#233;fica e segura em pacientes selecionados com IAMCSST.<sup><xref ref-type="bibr" rid="B8">8</xref> - <xref ref-type="bibr" rid="B10">10</xref></sup></p>
      <p>Com base nesses achados, o <italic>American College of Cardiology</italic> (ACC) e a <italic>American Heart Association</italic> (AHA), em 2015, atualizaram a recomenda&#231;&#227;o anterior, sendo, ent&#227;o, fact&#237;vel tanto a RC quanto a abordagem estadiada na ocasi&#227;o da ICP prim&#225;ria em pacientes hemodinamicamente est&#225;veis.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> A diretriz da Sociedade Europeia de Cardiologia (ESC), de 2017, segue a mesma orienta&#231;&#227;o.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> J&#225; a diretriz da Sociedade Brasileira de Cardiologia (SBC), de 2015, considera razo&#225;vel o tratamento de estenose grave de menor complexidade localizada no sistema coron&#225;rio relacionado ao vaso infartado.<sup><xref ref-type="bibr" rid="B12">12</xref></sup> Por outro lado, salienta que estes pacientes apresentam maior propens&#227;o &#224; ocorr&#234;ncia de novos eventos coron&#225;rios no per&#237;odo de 1 ano, sugerindo, ent&#227;o, que as estenoses coron&#225;rias graves n&#227;o relacionadas diretamente ao procedimento &#237;ndice devam ser abordadas em um segundo tempo, de forma estadiada.<sup><xref ref-type="bibr" rid="B12">12</xref></sup></p>
      <p>Neste estudo, objetivamos avaliar os desfechos de vida real relacionados a RC <italic>versus</italic> tratamento da art&#233;ria culpada em pacientes multiarteriais com IAMCSST em dois hospitais da Regi&#227;o Sul do Brasil.</p>
    </sec>
    <sec sec-type="methods">
      <title>M&#233;todo</title>
      <sec>
        <title>Delineamento da Pesquisa</title>
        <p>Estudo de registro, com pacientes hospitalizados por IAMCSST e DAC multiarterial em dois centros no Sul do Brasil. Foram coletados dados prospectivos no per&#237;odo de outubro de 2015 a mar&#231;o de 2016, com informa&#231;&#245;es da interna&#231;&#227;o hospitalar. Foram ainda coletados dados retrospectivos no per&#237;odo de janeiro a setembro de 2015, por revis&#227;o de prontu&#225;rio m&#233;dico. Os desfechos prim&#225;rio e secund&#225;rio foram avaliados prospectivamente por contato telef&#244;nico mensal, durante 12 meses ap&#243;s alta hospitalar ap&#243;s evento &#237;ndice.</p>
      </sec>
      <sec>
        <title>Sele&#231;&#227;o de Pacientes</title>
        <p>Foram inclu&#237;dos pacientes com idade &#8805; 18 anos e de ambos os sexos, admitidos nos hospitais supracitados no per&#237;odo de 6 meses, com o diagn&#243;stico de IAMCSST, tratados com ICP prim&#225;ria e DAC multiarterial &#224; cineangiocoronariografia &#8211; definida como presen&#231;a de les&#227;o igual ou superior a 70% pela an&#225;lise visual da angiografia em duas ou mais proje&#231;&#245;es, em mais de uma art&#233;ria coron&#225;ria. Pacientes encaminhados a esses hospitais para angioplastia de resgate ap&#243;s o uso de trombol&#237;ticos e que apresentavam DAC multiarterial tamb&#233;m foram eleg&#237;veis.</p>
        <p>Foram exclu&#237;dos pacientes com cirurgia de revasculariza&#231;&#227;o do mioc&#225;rdio (CRM) pr&#233;via, choque cardiog&#234;nico na admiss&#227;o, indica&#231;&#227;o de CRM ap&#243;s angioplastia prim&#225;ria, les&#227;o no tronco da coron&#225;ria esquerda, les&#227;o na art&#233;ria descendente anterior (ADA) proximal ou na art&#233;ria circunflexa proximal ou oclus&#227;o cr&#244;nica em art&#233;ria n&#227;o culpada pelo infarto (ANCI), os quais, pela avalia&#231;&#227;o da equipe assistente, se beneficiariam de cirurgia de revasculariza&#231;&#227;o.</p>
      </sec>
      <sec>
        <title>Coleta de Dados</title>
        <p>A coleta das informa&#231;&#245;es pertinentes ao estudo ocorreu em formul&#225;rio padronizado durante o per&#237;odo de hospitaliza&#231;&#227;o para o tratamento do evento agudo, incluindo caracter&#237;sticas demogr&#225;ficas, exames realizados na emerg&#234;ncia do hospital, resultado da cinecoronariografia, tratamento institu&#237;do, al&#233;m dos dados de seguimento pelo per&#237;odo de 1 ano. As condutas adotadas durante o atendimento do paciente foram de responsabilidade da equipe assistencial, sem influ&#234;ncia dos pesquisadores. A pesquisa se deu em conformidade com a resolu&#231;&#227;o n&#186; 466/2012 e foi aprovada pelos Comit&#234;s de &#201;tica e Pesquisa de ambas institui&#231;&#245;es. Os pacientes inclu&#237;dos prospectivamente assinaram o termo de consentimento livre e esclarecido (TCLE) ap&#243;s o t&#233;rmino do exame inicial (cinecoronariografia); para a coleta de dados retrospectivos, os pesquisadores assinaram o termo de sigilo de dados.</p>
      </sec>
      <sec>
        <title>Seguimento e Desfechos de Interesse</title>
        <p>A evolu&#231;&#227;o e ocorr&#234;ncia dos desfechos intra-hospitalares foram avaliados durante a hospitaliza&#231;&#227;o e, posteriormente, atrav&#233;s de busca ativa via contato telef&#244;nico e revis&#227;o de prontu&#225;rio m&#233;dico. O desfecho prim&#225;rio foi definido como a ocorr&#234;ncia de: (1) &#243;bito por causa cardiovascular; (2) reinfarto &#8211; definido como recorr&#234;ncia da dor isqu&#234;mica (embora n&#227;o seja imprescind&#237;vel), nova eleva&#231;&#227;o de segmento ST &#8805; 0,1 mV ou nova onda Q, no m&#237;nimo em duas deriva&#231;&#245;es cont&#237;guas ou valor de marcadores s&#233;ricos (troponina ou CK-MB) alterados (acima do limite superior do normal conforme valor de refer&#234;ncia do laborat&#243;rio local ou pelo menos 50% acima do valor do exame anterior); ou (3) angina recorrente &#8211; definida como retorno da dor, necessidade de uso de nitrato sublingual ou reinterna&#231;&#227;o por angina recorrente.</p>
        <p>O desfecho secund&#225;rio foi composto de: (1) acidente vascular encef&#225;lico (AVE); (2) parada cardiorrespirat&#243;ria (PCR) n&#227;o fatal; (3) sangramento maior (definido como necessidade de transfus&#227;o sangu&#237;nea por queda de mais de 3 g/dL no exame de hemoglobina, e/ou hemoglobina abaixo de 10 g/dL, e/ou instabilidade hemodin&#226;mica, e/ou prolongamento na interna&#231;&#227;o por sangramento maior, e/ou AVE hemorr&#225;gico, ou (4) necessidade de reinterven&#231;&#227;o percut&#226;nea ou cir&#250;rgica n&#227;o programada.</p>
      </sec>
      <sec>
        <title>An&#225;lise Estat&#237;stica</title>
        <p>A an&#225;lise estat&#237;stica foi realizada atrav&#233;s do IBM SPSS Statistics, vers&#227;o 22.0 para Windows. A idade e o tempo entre a ICP prim&#225;ria e o novo procedimento foram descritas como m&#233;dia &#177; desvio padr&#227;o. As vari&#225;veis categ&#243;ricas foram descritas como frequ&#234;ncia absoluta e relativa. As distribui&#231;&#245;es das vari&#225;veis num&#233;ricas foram comparadas entre os grupos tratados com RC ou apenas da les&#227;o culpada pelo infarto utilizando-se an&#225;lise de vari&#226;ncia com um crit&#233;rio de classifica&#231;&#227;o e, das vari&#225;veis categ&#243;ricas, utilizando-se o qui-quadrado de Pearson com corre&#231;&#227;o de continuidade ou teste exato de Fischer quando adequado. A chance de ocorr&#234;ncia de desfecho prim&#225;rio, secund&#225;rio e &#243;bito por qualquer causa foi comparada entre os grupos acima descritos utilizando-se regress&#227;o log&#237;stica bin&#225;ria. Na an&#225;lise multivari&#225;vel, os modelos foram comparados entre si utilizando-se o teste da raz&#227;o de verossimilhan&#231;a. As curvas de Kaplan-Meier para IAMCSST foram calculadas para RC e RI. As diferen&#231;as na taxa de sobrevida foram avaliadas pelo teste log-rank. As raz&#245;es de chance foram descritas com os respectivos intervalos de confian&#231;a de 95%. Considerou-se como estatisticamente significativos testes com valor de probabilidade &lt; 0,05.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Resultados</title>
      <p>No per&#237;odo de janeiro de 2015 a mar&#231;o de 2016, foram admitidos nas emerg&#234;ncias dos dois centros 248 pacientes com diagn&#243;stico de IAMCSST; destes, 85 (34,3%) pacientes apresentavam DAC multiarterial.</p>
      <p>Do total de 85 pacientes, 58 (68,2%) receberam estrat&#233;gia de RC e 27 (31,8%) receberam estrat&#233;gia de revasculariza&#231;&#227;o apenas da ACI. A idade m&#233;dia foi 62&#177;12 anos, e 61 (71,8%) participantes eram do sexo masculino. O infarto de parede inferior ocorreu em 42 (49,4%) pacientes, seguido pelo infarto de parede anterior em 37 (43,5%). Os pacientes classificados como Killip I na admiss&#227;o foram 71 (83,5%) e 67 (78,8%) apresentavam doen&#231;a coron&#225;ria biarterial. A ADA foi a respons&#225;vel pelo infarto em 32 (37,6%) casos, em 36 (42,4%), a les&#227;o foi considerada relacionada ao infarto e 17 (20,0%) pacientes n&#227;o apresentavam les&#245;es significativas nessa art&#233;ria, conforme descrito na <xref ref-type="table" rid="t1">Tabela 1</xref> . N&#227;o houve diferen&#231;a estatisticamente significativa entre as duas estrat&#233;gias de revasculariza&#231;&#227;o em nenhuma das caracter&#237;sticas analisadas, incluindo o tempo porta-bal&#227;o entre os grupos.</p>
      <p>
        <table-wrap id="t1">
          <label>Tabela 1</label>
          <caption>
            <title>&#8211; Caracter&#237;sticas cl&#237;nicas e demogr&#225;ficas da popula&#231;&#227;o em estudo (n = 85)</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="20%">
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" style="font-weight:normal"> </th>
                <th align="left" style="font-weight:normal"> </th>
                <th colspan="2">Estrat&#233;gia de revasculariza&#231;&#227;o</th>
                <th align="left" style="font-weight:normal"> </th>
              </tr>
              <tr>
                <th align="left" style="font-weight:normal"> </th>
                <th>Global</th>
                <th>Completa</th>
                <th>Incompleta</th>
                <th>p</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>
                  <bold>Centro</bold>
                </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">0,43</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>1</italic>
                </td>
                <td align="center">28 (32,9%)</td>
                <td align="center">17 (60,7%)</td>
                <td align="center">11 (39,3%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>2</italic>
                </td>
                <td align="center">57 (67,1%)</td>
                <td align="center">41 (71,9%)</td>
                <td align="center">16 (28,1%)</td>
                <td> </td>
              </tr>
              <tr>
                <td><bold>Idade</bold> (anos)</td>
                <td align="center">62&#177;12</td>
                <td align="center">62,7&#177;12</td>
                <td align="center">60,6&#177;13</td>
                <td align="center">0,46</td>
              </tr>
              <tr>
                <td>
                  <bold>Sexo masculino</bold>
                </td>
                <td align="center">61 (71,8%)</td>
                <td align="center">42 (72,4%)</td>
                <td align="center">19 (74,0%)</td>
                <td align="center">0,99</td>
              </tr>
              <tr>
                <td>
                  <bold>Ra&#231;a branca</bold>
                </td>
                <td align="center">80 (94,1%)</td>
                <td align="center">55 (94,8%)</td>
                <td align="center">25 (92,6%)</td>
                <td align="center">0,99</td>
              </tr>
              <tr>
                <td>
                  <bold>Hist&#243;ria pr&#233;via</bold>
                </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>HAS</italic>
                </td>
                <td align="center">54 (63,5%)</td>
                <td align="center">37 (63,8%)</td>
                <td align="center">17 (63,0%)</td>
                <td align="center">0,99</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>DM</italic>
                </td>
                <td align="center">22 (25,9%)</td>
                <td align="center">14 (24,1%)</td>
                <td align="center">8 (29,6%)</td>
                <td align="center">0,79</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>Tabagismo</italic>
                </td>
                <td align="center">26 (30,6%)</td>
                <td align="center">21 (36,2%)</td>
                <td align="center">5 (18,5%)</td>
                <td align="center">0,16</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>DAC pr&#233;via</italic>
                </td>
                <td align="center">10 (11,8%)</td>
                <td align="center">5 (8,6%)</td>
                <td align="center">5 (18,5%)</td>
                <td align="center">0,34</td>
              </tr>
              <tr>
                <td>
                  <bold>Localiza&#231;&#227;o do IAM</bold>
                </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">0,94*</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>Anterior</italic>
                </td>
                <td align="center">37 (43,5%)</td>
                <td align="center">26 (44,8%)</td>
                <td align="center">11 (40,7%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>Inferior</italic>
                </td>
                <td align="center">42 (49,4%)</td>
                <td align="center">28 (48,3%)</td>
                <td align="center">14 (51,9%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>Lateral</italic>
                </td>
                <td align="center">6 (7,1%)</td>
                <td align="center">4 (6,9%)</td>
                <td align="center">2 (7,4%)</td>
                <td> </td>
              </tr>
              <tr>
                <td>
                  <bold>BRE</bold>
                </td>
                <td align="center">4 (4,7%)</td>
                <td align="center">2 (3,4%)</td>
                <td align="center">2 (7,4%)</td>
                <td align="center">0,80*</td>
              </tr>
              <tr>
                <td>
                  <bold>N&#186; de estenoses</bold>
                </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">0,87</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>2</italic>
                </td>
                <td align="center">67 (78,8%)</td>
                <td align="center">46 (79,3%)</td>
                <td align="center">21 (77,8%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>3</italic>
                </td>
                <td align="center">18 (21,1%)</td>
                <td align="center">12 (20,7%)</td>
                <td align="center">6 (22,2%)</td>
                <td> </td>
              </tr>
              <tr>
                <td>
                  <bold>ADA</bold>
                </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">0,28</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>Culpada</italic>
                </td>
                <td align="center">32 (37,6%)</td>
                <td align="center">22 (37,9%)</td>
                <td align="center">10 (37,0%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>N&#227;o culpada</italic>
                </td>
                <td align="center">36 (42,4%)</td>
                <td align="center">27 (46,6%)</td>
                <td align="center">9 (33,3%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>Sem les&#227;o</italic>
                </td>
                <td align="center">17 (20,0%)</td>
                <td align="center">9 (15,5%)</td>
                <td align="center">8 (29,6%)</td>
                <td> </td>
              </tr>
              <tr>
                <td>
                  <bold>FEVE &lt; 50%</bold>
                </td>
                <td align="center">41 (48,2%)</td>
                <td align="center">25 (43,1%)</td>
                <td align="center">16 (59,3%)</td>
                <td align="center">0,25</td>
              </tr>
              <tr>
                <td>
                  <bold>Killip</bold>
                </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td align="center">0,62*</td>
              </tr>
              <tr>
                <td align="right">
                  <italic>1</italic>
                </td>
                <td align="center">71 (83,5%)</td>
                <td align="center">50 (86,2%)</td>
                <td align="center">21 (77,8%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>2</italic>
                </td>
                <td align="center">7 (8,2%)</td>
                <td align="center">4 (6,9%)</td>
                <td align="center">3 (11,1%)</td>
                <td> </td>
              </tr>
              <tr>
                <td align="right">
                  <italic>3</italic>
                </td>
                <td align="center">7 (8,2%)</td>
                <td align="center">4 (6,9%)</td>
                <td align="center">3 (11,1%)</td>
                <td> </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="TFN1">
              <p>
                <italic>Valores expressam m&#233;dia &#177; desvio padr&#227;o ou frequ&#234;ncia absoluta e relativa. p: valor de probabilidade; para idade, an&#225;lise de vari&#226;ncia; demais, qui-quadrado de Pearson ou *teste exato de Fischer. HAS: hipertens&#227;o arterial sist&#234;mica; DM: diabetes mellitus; DAC: doen&#231;a arterial coronariana; IAM: infarto agudo do mioc&#225;rdio; BRE: bloqueio de ramo esquerdo; ADA: art&#233;ria descendente anterior; FEVE: fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo.</italic>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <sec>
        <title>Interven&#231;&#227;o Coronariana</title>
        <p>Dos 58 pacientes que receberam estrat&#233;gia de RC, 6 (10,3%) realizaram tratamento completo no evento &#237;ndice &#8211; todos apresentavam doen&#231;a biarterial, sendo o tratamento da ANCI em 4 pacientes para o ramo diagonal e em 2 pacientes, para ADA. Os demais 52 pacientes realizaram o tratamento da ANCI de forma estadiada, sendo 38 na mesma interna&#231;&#227;o e 14 em interna&#231;&#227;o posterior. O tempo m&#233;dio entre a ICP prim&#225;ria e o novo procedimento foi de 13&#177;11 dias (variando entre 3 e 40 dias). Os detalhes referentes ao tratamento (ICP e terapia medicamentosa) est&#227;o descritos na <xref ref-type="table" rid="t2">Tabela 2</xref> .</p>
        <p>
          <table-wrap id="t2">
            <label>Tabela 2</label>
            <caption>
              <title>&#8211; Interven&#231;&#227;o coronariana e terapia medicamentosa (n = 85)</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="20%">
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th align="left" style="font-weight:normal"> </th>
                  <th colspan="2">Estrat&#233;gia de revasculariza&#231;&#227;o</th>
                  <th align="left" style="font-weight:normal"> </th>
                </tr>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th>Global</th>
                  <th>Completa</th>
                  <th>Incompleta</th>
                  <th>p</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>
                    <bold>Trombol&#237;tico pr&#233;vio</bold>
                  </td>
                  <td align="center">3 (3,5%)</td>
                  <td align="center">3 (5,2%)</td>
                  <td align="center">0</td>
                  <td align="center">0,57*</td>
                </tr>
                <tr>
                  <td>
                    <bold>Tipo de stent</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0,30*</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Convencional</italic>
                  </td>
                  <td align="center">76 (89,4%)</td>
                  <td align="center">50 (86,2%)</td>
                  <td align="center">26 (96,3%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Farmacol&#243;gico</italic>
                  </td>
                  <td align="center">9 (10,6%)</td>
                  <td align="center">8 (13,8%)</td>
                  <td align="center">1 (3,7%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td>
                    <bold>Inibidores da Glicoprote&#237;na IIb/IIIa</bold>
                  </td>
                  <td align="center">23 (27,1%)</td>
                  <td align="center">14 (24,1%)</td>
                  <td align="center">9 (33,3%)</td>
                  <td align="center">0,53</td>
                </tr>
                <tr>
                  <td>
                    <bold>Terapia cl&#237;nica em 24h</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>AAS</italic>
                  </td>
                  <td align="center">85 (100%)</td>
                  <td align="center">58 (100%)</td>
                  <td align="center">27 (100%)</td>
                  <td align="center">-</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Clopidogrel</italic>
                  </td>
                  <td align="center">85 (100%)</td>
                  <td align="center">58 (100%)</td>
                  <td align="center">27 (100%)</td>
                  <td align="center">-</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Estatina</italic>
                  </td>
                  <td align="center">85 (100%)</td>
                  <td align="center">58 (100%)</td>
                  <td align="center">27 (100%)</td>
                  <td align="center">-</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Betabloqueador</italic>
                  </td>
                  <td align="center">43 (50,6%)</td>
                  <td align="center">26 (44,8%)</td>
                  <td align="center">17 (63,0%)</td>
                  <td align="center">0,19</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>IECA/BRA</italic>
                  </td>
                  <td align="center">40 (47,1%)</td>
                  <td align="center">27 (46,6%)</td>
                  <td align="center">13 (48,1%)</td>
                  <td align="center">0,99</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Nitrato</italic>
                  </td>
                  <td align="center">30 (35,3%)</td>
                  <td align="center">20 (34,5%)</td>
                  <td align="center">10 (37,0%)</td>
                  <td align="center">0,99</td>
                </tr>
                <tr>
                  <td>
                    <bold>Escore SYNTAX</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0,34*</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Baixo</italic>
                  </td>
                  <td align="center">41 (48,2%)</td>
                  <td align="center">30 (51,7%)</td>
                  <td align="center">11 (40,7%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Moderado</italic>
                  </td>
                  <td align="center">44 (51,8%)</td>
                  <td align="center">28 (48,3%)</td>
                  <td align="center">16 (59,3%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Alto</italic>
                  </td>
                  <td align="center">&#8212;</td>
                  <td align="center">&#8212;</td>
                  <td align="center">&#8212;</td>
                  <td> </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN2">
                <p>
                  <italic>Valores expressam m&#233;dia &#177; desvio padr&#227;o ou frequ&#234;ncia absoluta e relativa. p: valor de probabilidade; para idade, an&#225;lise de vari&#226;ncia; demais, qui-quadrado de Pearson ou *teste exato de Fischer. HAS: hipertens&#227;o arterial sist&#234;mica; DM: diabetes mellitus; DAC: doen&#231;a arterial coronariana; IAM: infarto agudo do mioc&#225;rdio; BRE: bloqueio de ramo esquerdo; ADA: art&#233;ria descendente anterior; FEVE: fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>Stents convencionais foram implantados em 76 (89,4%) pacientes. Todos receberam dupla antiagrega&#231;&#227;o e estatina nas primeiras 24 horas. O uso de glicoprote&#237;na IIb/IIIa ocorreu em 23 (27,1%) casos. Com rela&#231;&#227;o ao escore SYNTAX, 41 (48,2%) pacientes apresentaram escore baixo, enquanto 44 (51,8%) apresentaram escore moderado. N&#227;o houve casos com escore SYNTAX alto e n&#227;o se observou diferen&#231;a estatisticamente significativa entre as duas estrat&#233;gias de revasculariza&#231;&#227;o quanto &#224; distribui&#231;&#227;o do escore.</p>
      </sec>
      <sec>
        <title>Desfechos Cl&#237;nicos</title>
        <p>A mortalidade geral foi de 8,2%, sendo que 86% dos &#243;bitos ocorreram no per&#237;odo intra-hospitalar. A chance de ocorr&#234;ncia tanto do desfecho prim&#225;rio quanto do secund&#225;rio foi significativamente maior entre os indiv&#237;duos tratados com RI quando comparados com aqueles tratados com RC [raz&#227;o de chances (OR) 5,1, intervalo de confian&#231;a de 95% (IC95%) 1,6-16,1 vs. OR 5,2, IC95% 1,2-22,9), respectivamente. Se analisada isoladamente a chance de &#243;bito cardiovascular, o resultado foi semelhante (OR 6,4, IC95% 1,2-35,3), conforme descrito na <xref ref-type="table" rid="t3">Tabela 3</xref> . Os &#243;bitos ocorreram predominantemente no per&#237;odo intra-hospitalar, com apenas um paciente na estrat&#233;gia de RI na fase tardia.</p>
        <p>
          <table-wrap id="t3">
            <label>Tabela 3</label>
            <caption>
              <title>&#8211; Desfechos cl&#237;nicos e estrat&#233;gia de revasculariza&#231;&#227;o (n = 85)</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="20%">
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th align="left" style="font-weight:normal"> </th>
                  <th colspan="2">Estrat&#233;gia de revasculariza&#231;&#227;o</th>
                  <th align="left" style="font-weight:normal"> </th>
                </tr>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th style="font-weight:normal">Completa n (%)</th>
                  <th style="font-weight:normal">Incompleta n (%)</th>
                  <th style="font-weight:normal">OR (IC95%)</th>
                  <th>p</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>
                    <bold>Desfecho prim&#225;rio (composto)</bold>
                  </td>
                  <td align="center">6 (10,3%)</td>
                  <td align="center">10 (37,0%)</td>
                  <td align="center">5,10 (1,6-16,1)</td>
                  <td align="center">0,005</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>&#211;bito Cardiovascular</italic>
                  </td>
                  <td align="center">2 (3,4%)</td>
                  <td align="center">5 (18,5%)</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Reinfarto</italic>
                  </td>
                  <td align="center">&#8212;</td>
                  <td align="center">&#8212;</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Angina</italic>
                  </td>
                  <td align="center">4 (6,9%)</td>
                  <td align="center">5 (18,5%)</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td>
                    <bold>Desfecho secund&#225;rio (composto)</bold>
                  </td>
                  <td align="center">3 (5,17%)</td>
                  <td align="center">6 (22,2%)</td>
                  <td align="center">5,24 (1,2-22,9)</td>
                  <td align="center">0,022</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>AVE</italic>
                  </td>
                  <td align="center">&#8212;</td>
                  <td align="center">&#8212;</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>PCR n&#227;o fatal</italic>
                  </td>
                  <td align="center">2 (3,4%)</td>
                  <td align="center">&#8212;</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Sangramento maior</italic>
                  </td>
                  <td align="center">1 (1,7%)</td>
                  <td align="center">&#8212;</td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Reinterven&#231;&#227;o</italic>
                  </td>
                  <td align="center">&#8212;</td>
                  <td align="center">6 (22,2%)</td>
                  <td> </td>
                  <td> </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN3">
                <p>
                  <italic>OR: raz&#227;o de chances; IC: intervalo de confian&#231;a; AVE: acidente vascular encef&#225;lico; PCR: parada cardiorrespirat&#243;ria.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>Conforme descrito na <xref ref-type="table" rid="t4">Tabela 4</xref> , observou-se, na an&#225;lise multivari&#225;vel, que a RC estava associada a menor chance de ocorr&#234;ncia dos desfechos prim&#225;rio e secund&#225;rio independente de sexo, idade, diabetes mellitus, les&#227;o na descendente anterior como culpada pelo infarto, presen&#231;a de les&#227;o na descendente anterior e fra&#231;&#227;o de eje&#231;&#227;o &lt; 50%. Ainda, a RC estava associada a menor chance de ocorr&#234;ncia do desfecho prim&#225;rio independente da parede ventricular acometida e da extens&#227;o da doen&#231;a coron&#225;ria. As curvas de Kaplan-Meier indicaram menor sobrevida em pacientes com doen&#231;a coronariana multiarterial p&#243;s-IAMCSST submetidos a RI em um per&#237;odo de 12 meses (p = 0,017) ( <xref ref-type="fig" rid="f01">Figura 1</xref> ).</p>
        <p>
          <table-wrap id="t4">
            <label>Tabela 4</label>
            <caption>
              <title>&#8211; Associa&#231;&#227;o independente entre estrat&#233;gia estadiada e incid&#234;ncia de desfecho prim&#225;rio e secund&#225;rio no seguimento de 1 ano (n = 85)</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="33%">
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th style="font-weight:normal">Desfecho prim&#225;rio* OR (IC95%)</th>
                  <th style="font-weight:normal">Desfecho secund&#225;rio<sup>&#8224;</sup> OR (IC95%)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>
                    <bold>N&#227;o ajustado</bold>
                  </td>
                  <td align="center">5,1 (1,6-16,1)</td>
                  <td align="center">5,2 (1,2-22,9)</td>
                </tr>
                <tr>
                  <td>
                    <bold>Modelo 2</bold>
                    <sup>
                      <bold>&#8225;</bold>
                    </sup>
                  </td>
                  <td align="center">5,2 (1,6-16,5)</td>
                  <td align="center">5,1 (1,1-23,0)</td>
                </tr>
                <tr>
                  <td>
                    <bold>Modelo 3</bold>
                    <sup>
                      <bold>&#167;</bold>
                    </sup>
                  </td>
                  <td align="center">5,1 (1,6-16,4)</td>
                  <td align="center">4,9 (1,1-23,1)</td>
                </tr>
                <tr>
                  <td>
                    <bold>Modelo 4</bold>
                    <sup>
                      <bold>//</bold>
                    </sup>
                  </td>
                  <td align="center">5,1 (1,6-16,4)</td>
                  <td align="center">5,1 (1,1-24,1)</td>
                </tr>
                <tr>
                  <td>
                    <bold>Modelo 5</bold>
                    <sup>
                      <bold>&#182;</bold>
                    </sup>
                  </td>
                  <td align="center">5,1 (1,6-16,7)</td>
                  <td align="center">4,3 (0,9-21,0)</td>
                </tr>
                <tr>
                  <td>
                    <bold>Modelo 6</bold>
                    <sup>
                      <bold>#</bold>
                    </sup>
                  </td>
                  <td align="center">4,6 (1,4-15,3)</td>
                  <td align="center">3,6 (0,7-19,6)</td>
                </tr>
                <tr>
                  <td>
                    <bold>Modelo 7**</bold>
                  </td>
                  <td align="center">4,7 (1,4-15,7)</td>
                  <td align="center">2,3 (0,4-14,2)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN4">
                <p>
                  <italic>OR: raz&#227;o de chances; IC: intervalo de confian&#231;a. *&#211;bito, reinfarto, angina; <sup>&#8224;</sup>Acidente vascular encef&#225;lico, parada cardiorrespirat&#243;ria n&#227;o fatal, sangramento, reinterven&#231;&#227;o. <sup>&#8225;</sup> Ajustado para idade e sexo &#167;Modelo 2 + ajuste para diabetes mellitus. //Modelo 3 + ajuste para art&#233;ria descendente anterior (ADA) culpada pelo evento. <sup>&#182;</sup>Modelo 4 + les&#227;o na ADA e fra&#231;&#227;o de eje&#231;&#227;o &lt; 50%. #Modelo 5 + local do infarto. *Modelo 6 + n&#250;mero de les&#245;es.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>
          <fig id="f01">
            <label>Figura 1</label>
            <caption>
              <title>&#8211; <italic>Sobrevida ap&#243;s revasculariza&#231;&#227;o completa (RC) e incompleta (RI) para infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST (IAMCSST) com doen&#231;a arterial coronariana (DAC) multiarterial em um per&#237;odo de 12 meses. *Teste de log-rank.</italic></title>
            </caption>
            <graphic xlink:href="1678-4170-abc-115-02-0229-80346-gf01.tif"/></fig>
        </p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discuss&#227;o</title>
      <p>Em registro real da pr&#225;tica cl&#237;nica, evidenciamos que a estrat&#233;gia de RC est&#225; associada &#224; redu&#231;&#227;o significativa de desfechos duros no seguimento de 1 ano quando comparada &#224; estrat&#233;gia de RI e que o tratamento das ANCIs durante a interven&#231;&#227;o coron&#225;ria prim&#225;ria &#233; incomum, sendo que a maioria dos pacientes com DAC multiarterial e IAMCSST receberam tratamento estadiado dentro de 40 dias do evento &#237;ndice.</p>
      <p>A presen&#231;a de DAC multiarterial ocorre em aproximadamente 40-50% dos pacientes com IAMCSST<sup><xref ref-type="bibr" rid="B3">3</xref> - <xref ref-type="bibr" rid="B4">4</xref></sup> e &#233; considerada um poderoso preditor independente de mortalidade.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Na nossa popula&#231;&#227;o em estudo, a preval&#234;ncia foi de cerca de 35%. A hist&#243;ria natural do IAMCSST demonstra que ocorrem dist&#250;rbios fisiopatol&#243;gicos mais generalizados, com potencial de comprometer a perfus&#227;o coronariana al&#233;m da distribui&#231;&#227;o da ACI, desestabilizando a placa ao longo do leito vascular coronariano.<sup><xref ref-type="bibr" rid="B13">13</xref></sup> O processo patol&#243;gico do IAMCSST envolve toda a &#225;rvore coronariana, sendo que a din&#226;mica desse processo inflamat&#243;rio espec&#237;fico &#233; maior no primeiro m&#234;s ap&#243;s o evento agudo,<sup><xref ref-type="bibr" rid="B14">14</xref></sup> possivelmente explicando o aumento da taxa de mortalidade nos primeiros 30 dias,<sup><xref ref-type="bibr" rid="B15">15</xref></sup> como visto no presente estudo. Devido ao pior progn&#243;stico desses pacientes, quando se examina o papel da RC no contexto do IAMCSST, deve-se considerar o impacto dos fatores supracitados na determina&#231;&#227;o de como uma estrat&#233;gia agressiva pode oferecer benef&#237;cio cl&#237;nico.<sup><xref ref-type="bibr" rid="B13">13</xref></sup></p>
      <p>Em conson&#226;ncia com as indica&#231;&#245;es das diretrizes contempor&#226;neas, ainda conservadoras, na pr&#225;tica cl&#237;nica do mundo real, v&#225;rios registros demonstram que a abordagem de m&#250;ltiplos vasos &#233; adotada entre 9% e 24,4%.<sup><xref ref-type="bibr" rid="B16">16</xref> - <xref ref-type="bibr" rid="B18">18</xref></sup> No registro portugu&#234;s ProACS ( <italic>Portuguese Registry of Acute Coronary Syndromes</italic> ), por exemplo, esse n&#250;mero &#233; de 19,2%. Neste estudo, a pr&#225;tica foi adotada em 68,2%. De acordo com alguns autores, a discrep&#226;ncia entre as diretrizes vigentes e a pr&#225;tica cl&#237;nica resulta de diversos fatores, desde a falta de evid&#234;ncias cl&#237;nicas at&#233; quest&#245;es econ&#244;micas envolvendo fontes pagadoras e protocolos vigentes. O assunto continua a suscitar debates e s&#243; poder&#225; ser resolvido com um estudo amplo e internacional.<sup><xref ref-type="bibr" rid="B19">19</xref></sup> No contexto do tratamento multiarterial, tamb&#233;m foi visto neste estudo a predomin&#226;ncia de pacientes biarteriais (78,8%), em concord&#226;ncia com estudos como o PRAMI,<sup><xref ref-type="bibr" rid="B7">7</xref></sup> e pacientes com menor complexidade de les&#245;es &#8211; n&#227;o houve casos de pacientes com escore SYNTAX alto &#8211;, o que nos leva &#224; reflex&#227;o de que, provavelmente, os pacientes mais graves &#8211; triarteriais e com escore SYNTAX alto &#8211; receberam indica&#231;&#227;o de tratamento cir&#250;rgico ap&#243;s a angioplastia prim&#225;ria nos centros estudados.</p>
      <p>Com rela&#231;&#227;o &#224; terapia farmacol&#243;gica, seguindo as diretrizes para IAMCSST, 100% dos pacientes receberam dupla antiagrega&#231;&#227;o plaquet&#225;ria e estatinas. O uso de inibidores da glicoprote&#237;na IIb/IIIa n&#227;o diferiu entre os grupos, ficando em torno de 27,1% dos casos, embora tenha sido amplamente avaliado por metan&#225;lise que concluiu que seus benef&#237;cios s&#227;o maiores em pacientes de alto risco, como naqueles submetidos &#224; RC.<sup><xref ref-type="bibr" rid="B20">20</xref></sup> Outro fator de destaque &#233; a alta taxa de uso de stent convencional &#8211; 89,4% dos casos &#8211;, o que difere dos ensaios cl&#237;nicos randomizados (ECRs) a respeito deste tema.<sup><xref ref-type="bibr" rid="B7">7</xref> - <xref ref-type="bibr" rid="B10">10</xref></sup> Tal fato chama a aten&#231;&#227;o para a disparidade entre os pacientes inclu&#237;dos em ECRs e os pacientes reais, o que refor&#231;a a import&#226;ncia de registros populacionais como esses. Embora os ECRs empreguem o delineamento mais amplamente aceito para comparar tratamentos, eles ainda t&#234;m deixado muitas quest&#245;es importantes sem resposta. Acredita-se que uma an&#225;lise cuidadosa das informa&#231;&#245;es de registros cl&#237;nicos ofere&#231;a uma abordagem complementar aos ensaios cl&#237;nicos, especialmente considerando a potencial inclus&#227;o de amostras mais representativas da popula&#231;&#227;o-alvo. Al&#233;m disso, devido ao fato de os ECRs serem realizados em centros de excel&#234;ncia, n&#227;o fica claro se seus resultados podem ser generalizados para a pr&#225;tica cl&#237;nica usual. A experi&#234;ncia do operador, por exemplo, varia entre as institui&#231;&#245;es e pode interferir no resultado. Atrav&#233;s de registros como o presente estudo, podemos perceber que, mesmo em condi&#231;&#245;es n&#227;o ideais, permanece significativo o benef&#237;cio da RC em pacientes multiarteriais.<sup><xref ref-type="bibr" rid="B21">21</xref></sup> Entre 2006 e 2010, o registro SCAAR ( <italic>Swedish Coronary Angiography and Angioplasty Registry</italic> ) acompanhou a evolu&#231;&#227;o de 23.342 pacientes com doen&#231;a de m&#250;ltiplos vasos que realizaram angioplastia coron&#225;ria com RI e sua poss&#237;vel associa&#231;&#227;o com morte, nova interven&#231;&#227;o e infarto agudo do mioc&#225;rdio a longo prazo. A RI no momento da alta hospitalar se associou a um alto risco de eventos card&#237;acos adversos em um ano, com um risco ajustado de morte e a combina&#231;&#227;o de morte/infarto de 1,29 (IC95% 1,12-1,49; p = 0,0005) e 1,42 (IC95% 1,30-1,56; p &lt; 0,0001), respectivamente.</p>
      <p>O principal achado deste estudo &#233; a demonstra&#231;&#227;o de significativo benef&#237;cio na redu&#231;&#227;o da mortalidade em pacientes submetidos &#224; RC, mesmo quando realizada de forma estadiada. Os casos de RC no evento &#237;ndice foram incomuns, realizados somente em pacientes biarteriais, com anatomia favor&#225;vel e menor gravidade na chegada (Killip I). Outro achado importante foi o significativo benef&#237;cio com rela&#231;&#227;o a revasculariza&#231;&#227;o repetida e angina recorrente. Em pacientes com IAMCSST tratados com ICP prim&#225;ria em hospitais reais, a RC n&#227;o aumenta a mortalidade em curto e longo prazos, mostrando-se segura quando realizada de forma estadiada.<sup><xref ref-type="bibr" rid="B22">22</xref></sup></p>
      <p>Embora o benef&#237;cio da estrat&#233;gia estadiada ap&#243;s a ICP prim&#225;ria tenha sido sugerido em diversos estudos, como neste, permanecem questionamentos a serem resolvidos, como o tempo apropriado para a ICP estadiada. Na pr&#225;tica cl&#237;nica, fatores como disfun&#231;&#227;o renal, complexidade das les&#245;es, volume de contraste, dose de radia&#231;&#227;o, estado hemodin&#226;mico e <italic>status</italic> do paciente podem influenciar a decis&#227;o pelo tempo ideal da revasculariza&#231;&#227;o. Uma pesquisa via eletr&#244;nica conduzida pela ACC revelou que, embora a maioria dos cardiologistas intervencionistas concorde em realizar a RC de forma estadiada, houve variabilidade significativa nas opini&#245;es no que se refere ao tempo ideal para a pr&#243;xima ICP. Somente 22% dos entrevistados realizavam a nova interven&#231;&#227;o na mesma hospitaliza&#231;&#227;o; a maioria recomendou um prazo acima de 15 dias para o segundo procedimento.<sup><xref ref-type="bibr" rid="B23">23</xref></sup></p>
      <p>Apesar das evid&#234;ncias e estudos em andamento, nenhum estudo pode ser capaz de definir uma estrat&#233;gia &#250;nica para pacientes com IAMCSST e DAC multiarterial. Como s&#227;o pacientes heterog&#234;neos, a estrat&#233;gia deve ser individualizada. Desnecess&#225;rio dizer que o foco deve ser no tratamento da les&#227;o culpada. A decis&#227;o deve levar em conta a complexidade anat&#244;mica, fun&#231;&#227;o ventricular e perfil do paciente, a fim de se buscar a melhor estrat&#233;gia, idealmente atrav&#233;s de um <italic>heart team</italic> . Uma estratifica&#231;&#227;o de risco completa, com dados cl&#237;nicos e angiogr&#225;ficos, &#233; crucial para a melhor avalia&#231;&#227;o destes pacientes.<sup><xref ref-type="bibr" rid="B24">24</xref></sup></p>
      <p>O presente estudo apresenta algumas limita&#231;&#245;es que devem ser consideradas, especialmente relacionadas ao seu car&#225;ter observacional. N&#227;o se pode excluir a possibilidade de vi&#233;s de sele&#231;&#227;o, apesar de n&#227;o se ter identificado diferen&#231;as estatisticamente significativas quanto &#224;s vari&#225;veis avaliadas em rela&#231;&#227;o &#224;s caracter&#237;sticas basais dos pacientes tratados com RC ou RI e de n&#227;o se ter observado modifica&#231;&#227;o do efeito da estrat&#233;gia sobre a ocorr&#234;ncia de desfecho prim&#225;rio pelos fatores considerados na an&#225;lise multivari&#225;vel, uma vez que a estrat&#233;gia de interven&#231;&#227;o ficou a crit&#233;rio do operador. Al&#233;m disso, trata-se de um estudo com n&#250;mero pequeno de pacientes de dois centros do Sul do Brasil, podendo n&#227;o ser representativo de realidades de outras regi&#245;es e servi&#231;os n&#227;o p&#250;blicos.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclus&#245;es</title>
      <p>No presente estudo, com dados reais da pr&#225;tica cl&#237;nica de dois centros do Sul do Brasil, encontramos que, em pacientes com DAC multiarterial no contexto do IAMCSST e submetidos &#224; ICP prim&#225;ria, a estrat&#233;gia de RC est&#225; associada com redu&#231;&#227;o significativa dos desfechos prim&#225;rio e secund&#225;rio no seguimento de 1 ano, quando comparada &#224; RI. Esses dados devem suscitar discuss&#227;o sobre os protocolos cl&#237;nicos e institucionais vigentes.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Sekercioglu N, Spencer FA, Lopes LC, Guyatt GH. Culprit vessel only vs immediate complete revascularization in patients with acute ST-Segment elevation myocardial infarction: systematic review and meta-analysis. Clin Cardiol. 2014;37(12):765-72.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sekercioglu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Guyatt</surname>
              <given-names>GH</given-names>
            </name>
          </person-group>
          <article-title>Culprit vessel only vs immediate complete revascularization in patients with acute ST-Segment elevation myocardial infarction: systematic review and meta-analysis</article-title>
          <source>Clin Cardiol</source>
          <year>2014</year>
          <volume>37</volume>
          <issue>12</issue>
          <fpage>765</fpage>
          <lpage>772</lpage>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Zhang D, Song X, Lv S, Yuan F, Xu F, Zhang M, et al. Culprit vessel only versus multivessel percutaneous coronary intervention in patients presenting with ST-segment elevation myocardial infarction and multivessel disease. PLoS One. 2014;9(3):e92316.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Culprit vessel only versus multivessel percutaneous coronary intervention in patients presenting with ST-segment elevation myocardial infarction and multivessel disease</article-title>
          <source>PLoS One</source>
          <year>2014</year>
          <volume>9</volume>
          <issue>3</issue>
          <elocation-id>e92316</elocation-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Park DW, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312(19):2019-27.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Clare</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Schulte</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Pieper</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Califf</surname>
              <given-names>RM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction</article-title>
          <source>JAMA</source>
          <year>2014</year>
          <volume>312</volume>
          <issue>19</issue>
          <fpage>2019</fpage>
          <lpage>2027</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. Levine GM, Bates ER, Balnkeship JC, Bailey SR, Bitti JA, Cercek J, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016;133:1135-47.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levine</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Balnkeship</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Bitti</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Cercek</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions</article-title>
          <source>Circulation</source>
          <year>2016</year>
          <volume>133</volume>
          <fpage>1135</fpage>
          <lpage>1147</lpage>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Wolny R, Pregowski J, Bekta P, Chmielak Z, Witkowski A. Early occlusion of the non-infarct-related coronary artery following successful primary percutaneous coronary intervention in ST-elevation myocardial infarction. Postepy Kardiol Interwencyjnej. 2015;11(2):136-40.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wolny</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pregowski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bekta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chmielak</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Witkowski</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Early occlusion of the non-infarct-related coronary artery following successful primary percutaneous coronary intervention in ST-elevation myocardial infarction</article-title>
          <source>Postepy Kardiol Interwencyjnej</source>
          <year>2015</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>136</fpage>
          <lpage>140</lpage>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Levine GM, Bates ER, Blankenship JC, Bailey SR, Bitti JA, Cercek J, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574&#8211;651.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levine</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Blankenship</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Bitti</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Cercek</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions</article-title>
          <source>Circulation</source>
          <year>2011</year>
          <volume>124</volume>
          <fpage>e574</fpage>
          <lpage>e651</lpage>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115-23.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wald</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Wald</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Chase</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>LO</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Randomized trial of preventive angioplasty in myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>369</volume>
          <issue>12</issue>
          <fpage>1115</fpage>
          <lpage>1123</lpage>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Kelly DJ, Mc Cann GP, Blackman D, Curzen NP, Dalby M, Grennwood JP, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65(10):963-72.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Mc Cann</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Blackman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Curzen</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Dalby</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grennwood</surname>
              <given-names>JP</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2015</year>
          <volume>65</volume>
          <issue>10</issue>
          <fpage>963</fpage>
          <lpage>972</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Hlinomaz O. Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE 13 trial. [citado 10 Set. 2015]. Dispon&#237;vel em: <ext-link ext-link-type="uri" xlink:href="http://sbhci.org.br/wp-content/uploads/2015/05/PRAGUE-13-Trial.pdf">http://sbhci.org.br/wp-content/uploads/2015/05/PRAGUE-13-Trial.pdf</ext-link>.</mixed-citation>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <name>
              <surname>Hlinomaz</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy</article-title>
          <source>PRAGUE 13 trial</source>
          <date-in-citation content-type="cited-date">citado 10 Set. 2015</date-in-citation>
          <ext-link ext-link-type="uri" xlink:href="http://sbhci.org.br/wp-content/uploads/2015/05/PRAGUE-13-Trial.pdf">http://sbhci.org.br/wp-content/uploads/2015/05/PRAGUE-13-Trial.pdf</ext-link>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. Engstr&#248;m T, Kelb&#230;k H, Helqvist S, Hofsten DE, Klovgaard L, Holmvang L, et al. Complete revascularization versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI 3-PRIMULTI): an open-label, randomized controlled trial. Lancet. 2015;386(9994):665-71.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engstr&#248;m</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kelb&#230;k</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Helqvist</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hofsten</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Klovgaard</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Holmvang</surname>
              <given-names>L</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Complete revascularization versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI 3-PRIMULTI): an open-label, randomized controlled trial</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>386</volume>
          <issue>9994</issue>
          <fpage>665</fpage>
          <lpage>671</lpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11. Ibanes B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ibanes</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Agewall</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Antunes</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Bucciarelli-Ducci</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bueno</surname>
              <given-names>H</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)</article-title>
          <source>Eur Heart J</source>
          <year>2018</year>
          <volume>39</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>177</lpage>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>12. Piegas LS, Timerman A, Feitosa GS, Nicolau JC, Mattos LAP, Andrade MD, et al. V Diretriz da Sociedade Brasileira de Cardiologia sobre Tratamento do Infarto Agudo do Mioc&#225;rdio com Supradesn&#237;vel do Segmento ST. Arq Bras Cardiol. 2015;105(2 Suppl 1):1-105.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piegas</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feitosa</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Nicolau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>LAP</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>MD</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>V Diretriz da Sociedade Brasileira de Cardiologia sobre Tratamento do Infarto Agudo do Mioc&#225;rdio com Supradesn&#237;vel do Segmento ST</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2015</year>
          <volume>105</volume>
          <issue>2</issue>
          <supplement>Suppl 1</supplement>
          <fpage>1</fpage>
          <lpage>105</lpage>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation>13. Pollack A, Mohanty BD, Handa R, Looser PM, Fuster V, King III Sb, et al. Preventive stenting in acute myocardial infarction. JACC Cardiovasc Interv. 2015;8(1 PtB):131-8.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pollack</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mohanty</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Handa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Looser</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>Sb</given-names>
              <suffix>III</suffix>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Preventive stenting in acute myocardial infarction.</article-title>
          <source>JACC Cardiovasc Interv</source>
          <year>2015</year>
          <volume>8</volume>
          <issue>1 PtB</issue>
          <fpage>131</fpage>
          <lpage>138</lpage>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation>14. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O&#180;Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343(13):915-22.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldstein</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Demetriou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Grines</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Pica</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shoukfeh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O&#180;Neill</surname>
              <given-names>WW</given-names>
            </name>
          </person-group>
          <article-title>Multiple complex coronary plaques in patients with acute myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <year>2000</year>
          <volume>343</volume>
          <issue>13</issue>
          <fpage>915</fpage>
          <lpage>922</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation>15. Lekston A, Tajstra M, Gasior M, Gierlotka M, Pres D, Hudzik B, et al. Impact of multivessel coronary disease on one-year clinical outcomes and five-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Kardio Pol. 2011;69(4):336-43.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lekston</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tajstra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gasior</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gierlotka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pres</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hudzik</surname>
              <given-names>B</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Impact of multivessel coronary disease on one-year clinical outcomes and five-year mortality in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention</article-title>
          <source>Kardio Pol</source>
          <year>2011</year>
          <volume>69</volume>
          <issue>4</issue>
          <fpage>336</fpage>
          <lpage>343</lpage>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation>16. Dziewierz A, Siudak Z, Rakowski T, Zasada W, Dubiel JS, Dudek D. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry). Am J Cardiol. 2010;106(3):342-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dziewierz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Siudak</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Rakowski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Zasada</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dubiel</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Dudek</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry)</article-title>
          <source>Am J Cardiol</source>
          <year>2010</year>
          <volume>106</volume>
          <issue>3</issue>
          <fpage>342</fpage>
          <lpage>347</lpage>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation>17. Bengalore S, Kumar S, Poddar KL, Ramasamy S, Rha SW, Faxon DP. Meta-analysis of multivessel coronary artery revascularization versus culprit only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. Am J Cardiol. 2011;107(9):1300-10.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bengalore</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Poddar</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Ramasamy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rha</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Faxon</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Meta-analysis of multivessel coronary artery revascularization versus culprit only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease</article-title>
          <source>Am J Cardiol</source>
          <year>2011</year>
          <volume>107</volume>
          <issue>9</issue>
          <fpage>1300</fpage>
          <lpage>1310</lpage>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation>18. Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, et al. Prognostic impact of staged versus &#8220;one-time&#8221; multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2011;58(7):704-11.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kornowski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mehran</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dangas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nikolsky</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Assali</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Claessen</surname>
              <given-names>BE</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Prognostic impact of staged versus &#8220;one-time&#8221; multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2011</year>
          <volume>58</volume>
          <issue>7</issue>
          <fpage>704</fpage>
          <lpage>711</lpage>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation>19. Santos AR, Pi&#231;arra BC, Celeiro M, Bento A, Aguiar J. Multivessel approach in ST-elevation myocardial infarction: impact on in-hospital morbidity and mortality. Rev Port Cardiol. 2014;33(2):67-73.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Pi&#231;arra</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Celeiro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bento</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aguiar</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Multivessel approach in ST-elevation myocardial infarction: impact on in-hospital morbidity and mortality</article-title>
          <source>Rev Port Cardiol</source>
          <year>2014</year>
          <volume>33</volume>
          <issue>2</issue>
          <fpage>67</fpage>
          <lpage>73</lpage>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation>20. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J. 2009;30(22):2705-13.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De Luca</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Navarese</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials</article-title>
          <source>Eur Heart J</source>
          <year>2009</year>
          <volume>30</volume>
          <issue>22</issue>
          <fpage>2705</fpage>
          <lpage>2713</lpage>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation>21. Califf RM, Pryor DB, Greenfield JC. Beyond randomized trials: applying clinical experience in the treatment of patients with coronary artery disease. Circulation. 1986;74(6):1191-94.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Califf</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Pryor</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Greenfield</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Beyond randomized trials: applying clinical experience in the treatment of patients with coronary artery disease</article-title>
          <source>Circulation</source>
          <year>1986</year>
          <volume>74</volume>
          <issue>6</issue>
          <fpage>1191</fpage>
          <lpage>1194</lpage>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation>22. Jensen LO, Thayssen P, Farkas DK, Hougaard M, Tekelsen CJ, Tilsted HH, et al. Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease. EuroIntervention. 2012;8(4):456-64.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jensen</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Thayssen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Farkas</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Hougaard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tekelsen</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Tilsted</surname>
              <given-names>HH</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Culprit only or multivessel percutaneous coronary interventions in patients with ST-segment elevation myocardial infarction and multivessel disease</article-title>
          <source>EuroIntervention</source>
          <year>2012</year>
          <volume>8</volume>
          <issue>4</issue>
          <fpage>456</fpage>
          <lpage>464</lpage>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation>23. Hambraeus K, Jensevik K, Lagerqvist B, Lindahl B, Carlsson R, Farzaneh-Far R, et al. Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry. JACC Cardiovasc Interv. 2016;9(3):207-15.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hambraeus</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jensevik</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lagerqvist</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lindahl</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Carlsson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Farzaneh-Far</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry</article-title>
          <source>JACC Cardiovasc Interv</source>
          <year>2016</year>
          <volume>9</volume>
          <issue>3</issue>
          <fpage>207</fpage>
          <lpage>215</lpage>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation>24. Cuisset T, Noc M. Multivessel PCI in STEMI: ready to be the recommended strategy? EuroIntervention. 2014;10(Suppl T):T47-54.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuisset</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Noc</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Multivessel PCI in STEMI: ready to be the recommended strategy?</article-title>
          <source>EuroIntervention</source>
          <year>2014</year>
          <volume>10</volume>
          <issue>Suppl T</issue>
          <fpage>T47</fpage>
          <lpage>T54</lpage>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>Vincula&#231;&#227;o Acad&#234;mica</p>
        <p>Este artigo &#233; parte de disserta&#231;&#227;o de Mestrado de Julia Cremona Cadore pela Universidade Federal do Rio Grande do Sul.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Fontes de Financiamento</p>
        <p>O presente estudo n&#227;o contou com fontes de financiamento externas.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="other">
        <label>ERRATA</label>
        <p>
          <bold>Edi&#231;&#227;o de Agosto de 2020, vol. 115 (2), p&#225;gs. 229-237</bold>
        </p>
        <p>No Artigo Original &#8220;Revasculariza&#231;&#227;o Completa Versus Tratamento da Art&#233;ria Culpada no Infarto com Supradesnivelamento do Segmento ST: Registro Multic&#234;ntrico&#8221; com, n&#250;mero de DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20180346">https://doi.org/10.36660/abc.20180346</ext-link>, publicado no peri&#243;dico Arquivos Brasileiros de Cardiologia, 115(2):229-237, na p&#225;gina 229, corrigir o nome do autor Alexandre Tognon para: Alexandre Pereira Tognon e autor Rog&#233;rio Tumelero para: Rog&#233;rio Tadeu Tumelero. Retirar a institui&#231;&#227;o: Universidade de Passo Fundo, Passo Fundo, RS - Brasil e alterar para: Associa&#231;&#227;o Hospitalar Beneficente S&#227;o Vicente de Paulo, Passo Fundo, RS - Brasil das afilia&#231;&#245;es dos autores Alexandre Pereira Tognon e Rog&#233;rio Tadeu Tumelero.</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Complete Revascularization Versus Treatment of the Culprit Artery Only in ST Elevation Myocardial Infarction: A Multicenter Registry</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cadore</surname>
            <given-names>Julia Cremona</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Furtado</surname>
            <given-names>Mariana Vargas</given-names>
          </name>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tumelero</surname>
            <given-names>Rog&#233;rio Tadeu</given-names>
          </name>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tognon</surname>
            <given-names>Alexandre Pereira</given-names>
          </name>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Krepsky</surname>
            <given-names>Ana Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cadore</surname>
            <given-names>Denis</given-names>
          </name>
          <xref ref-type="aff" rid="aff3001">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0002-0812-920X</contrib-id>
          <name>
            <surname>Ruschel</surname>
            <given-names>Karen Brasil</given-names>
          </name>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bedin</surname>
            <given-names>Julia Caldas</given-names>
          </name>
          <xref ref-type="aff" rid="aff4001">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Conte</surname>
            <given-names>Thais</given-names>
          </name>
          <xref ref-type="aff" rid="aff4001">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Polanczyk</surname>
            <given-names>Carisi Anne</given-names>
          </name>
          <xref ref-type="aff" rid="aff5001">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Universidade Federal do Rio Grande do Sul - PPG Ci&#234;ncias Cardiovasculares: Cardiologia, Porto Alegre, RS - Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital de Cl&#237;nicas de Porto Alegre - Instituto de Avalia&#231;&#227;o de Tecnologia em Sa&#250;de, Porto Alegre, RS - Brazil</institution>
      </aff>
      <aff id="aff3001">
        <label>3</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Associa&#231;&#227;o Hospitalar Beneficente S&#227;o Vicente de Paulo, Passo Fundo, RS - Brasil</institution>
      </aff>
      <aff id="aff4001">
        <label>4</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Universidade Federal do Rio Grande do Sul - Faculdade de Medicina, Porto Alegre, RS - Brazil</institution>
      </aff>
      <aff id="aff5001">
        <label>5</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital de Cl&#237;nicas de Porto Alegre, Porto Alegre, RS &#8211; Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001">Mailing Address: Carisi Anne Polanczyk &#8226; Hospital de Cl&#237;nicas de Porto Alegre - Instituto de Avalia&#231;&#227;o de Tecnologia em Sa&#250;de - Rua Ramiro Barcelos, 2350. Postal Code 90035-903, Porto Alegre, RS &#8211; Brazil E-mail: carisi.anne@gmail.com</corresp>
        <fn fn-type="con">
          <p>Author Contributions</p>
          <p>Conception and design of the research: Cadore JC, Furtado MV, Tumelero R, Tognon A, Krepsky AM, Cadore D, Polanczyk CA; Data acquisition: Cadore JC, Tumelero R, Krepsky AM, Cadore D, Bedin JC, Conte T; Analysis and interpretation of the data: Cadore JC, Furtado MV, Tognon A, Ruschel KB, Polanczyk CA; Statistical analysis: Cadore JC, Tognon A, Polanczyk CA; Writing of the manuscript: Cadore JC, Tognon A, Cadore D; Critical revision of the manuscript for intellectual content: Furtado MV, Ruschel KB, Polanczyk CA.</p>
        </fn>
        <fn fn-type="conflict">
          <p>Potential Conflict of Interest</p>
          <p>The authors report no conflict of interest concerning the materials and methods used in this study or the findings specified in this paper.</p>
        </fn>
      </author-notes>
      <abstract>
        <title>Abstract</title>
        <sec>
          <title>Background</title>
          <p>Data on the management and prognosis of patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease are limited in Brazil, showing that the available revascularization strategies should be investigated</p>
        </sec>
        <sec>
          <title>Objective</title>
          <p>To assess the outcomes of complete revascularization versus treatment of the culprit artery only in patients with STEMI and multivessel disease.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>A prospective cohort study was conducted at two medical centers in southern Brazil with a 1-year follow-up after the index procedure. The primary outcome was a composite of cardiac death, reinfarction, or recurrent angina, while the secondary outcome was stroke, nonfatal cardiac arrest, major bleeding, or need for reintervention. The probability of outcomes occurring was compared between the groups using binary logistic regression. A p-value &lt; 0.05 was considered statistically significant.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Eighty-five patients were included. Their mean age was 62&#177;12 years, and 61 (71.8%) were male. Fifty-eight (68.2%) were treated with complete revascularization and 27 (31.8%) with incomplete revascularization. The chance of both the primary and secondary outcomes occurring was significantly greater among patients treated with incomplete revascularization when compared to those treated with complete revascularization (odds ratio [OR] 5.1, 95% confidence interval [CI] 1.6-16.1 vs. OR 5.2, 95% CI 1.2-22.9, respectively), as well as cardiac death (OR 6.4, 95% CI 1.2-35.3).</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Registry data from two centers in southern Brazil demonstrate that the complete revascularization strategy is associated with a significant reduction in primary and secondary outcomes in a 1-year follow-up when compared to the incomplete revascularization strategy (Arq Bras Cardiol. 2020; 115(2):229-237)</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>ST Elevation Myocardial Infarction/mortality, Cohort Studies</kwd>
        <kwd>Hemodynamic</kwd>
        <kwd>Death Certificates</kwd>
        <kwd>Angina Pectoris</kwd>
        <kwd>Stroke</kwd>
        <kwd>Heart Arrest</kwd>
        <kwd>Angina Pectoris</kwd>
        <kwd>Stroke</kwd>
        <kwd>Heart Arrest</kwd>
        <kwd>Percutaneous Coronary Interventions</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>ST-segment elevation myocardial infarction (STEMI) is an extremely relevant public health issue<sup><xref ref-type="bibr" rid="B1">1</xref></sup> with a high mortality rate if not properly treated.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Approximately 50% of patients present with multivessel coronary artery disease (CAD),<sup><xref ref-type="bibr" rid="B3">3</xref> - <xref ref-type="bibr" rid="B4">4</xref></sup> in which case prognosis is even more unfavorable.<sup><xref ref-type="bibr" rid="B5">5</xref></sup></p>
        <p>Therapeutic options for this complex group of patients with STEMI and multivessel disease include primary percutaneous coronary intervention (PCI) in the culprit artery and PCI in the other stenoses only for spontaneous ischemia or risk findings in noninvasive tests (incomplete revascularization &#8211; IR); multivessel PCI at the time of primary PCI (complete revascularization &#8211; CR); primary PCI in the culprit artery and staged approach of the other stenoses (staged CR). Initial studies showed conflicting results.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> The PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) study, however, led to a paradigm shift as it demonstrated the benefit of multivessel PCI compared to culprit-artery-only PCI.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Other trials reinforced the hypothesis that a CR strategy could be beneficial and safe in selected patients with STEMI.<sup><xref ref-type="bibr" rid="B8">8</xref> - <xref ref-type="bibr" rid="B10">10</xref></sup></p>
        <p>Based on those findings, the American College of Cardiology (ACC) and the American Heart Association (AHA) updated their guidelines in 2015 with recommendations for both CR and staged approach at the time of primary PCI in hemodynamically stable patients.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> The 2017 European Society of Cardiology (ESC) guideline followed the same path.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> The 2015 Brazilian Society of Cardiology (SBC) guideline, in turn, finds it reasonable to treat less complex, severe stenosis located in the coronary system linked to the infarct-related vessel.<sup><xref ref-type="bibr" rid="B12">12</xref></sup> Conversely, the guideline highlights that these patients are more likely to experience new coronary events within 1 year, thus suggesting that severe coronary stenoses that are not directly related to the index procedure should be managed later with a staged approach.<sup><xref ref-type="bibr" rid="B12">12</xref></sup></p>
        <p>In this study, we aimed to assess real-life outcomes of CR versus treatment of the culprit artery only in patients with STEMI and multivessel disease managed at two hospitals in southern Brazil.</p>
      </sec>
      <sec sec-type="methods">
        <title>Method</title>
        <sec>
          <title>Study Design</title>
          <p>A registry study was conducted to evaluate patients with STEMI and multivessel CAD admitted to two medical centers in southern Brazil. Prospective data were collected from October 2015 to March 2016 using hospital admission information. Also, retrospective data were collected from January to September 2015 by reviewing medical records. Primary and secondary outcomes were prospectively assessed by monthly telephone contact for 12 months following hospital discharge for the index event.</p>
        </sec>
        <sec>
          <title>Patient Selection</title>
          <p>Male and female patients were included if they were aged &#8805; 18 years, were admitted to the study centers in the 6-month period, had diagnosis of STEMI treated with primary PCI, and presented with multivessel CAD on coronary angiography &#8211; defined as the presence of a lesion &#8805; 70% by visual assessment of the angiogram in at least two projections in more than one coronary artery. Patients who were referred to the hospitals for rescue angioplasty after thrombolytic therapy and had multivessel CAD were also eligible.</p>
          <p>Patients were excluded if they had undergone previous coronary artery bypass grafting (CABG), had cardiogenic shock at admission, indication for CABG following primary angioplasty, left main coronary artery disease, lesion in the proximal portion of the left anterior descending artery (LAD) or the circumflex artery, or chronic total occlusion of a nonculprit artery (cases which would benefit from CABG at the discretion of the health care team).</p>
        </sec>
        <sec>
          <title>Data Collection</title>
          <p>Study data were collected using a standardized form for the period of hospitalization for treatment of the acute event, including demographic characteristics, tests performed in the emergency department, coronary angiography results, administered treatment, as well as follow-up data for a 1-year period. All procedures related to patient care were the responsibility of the health care team, with no influence from the researchers. The study was conducted in accordance with Brazilian resolution no. 466/2012 and was approved by the Research Ethics Committees at both institutions. The prospectively enrolled patients signed an informed consent form after the initial test (coronary angiography); for retrospective data collection, the researchers signed a data confidentiality agreement.</p>
        </sec>
        <sec>
          <title>Follow-up and Outcomes of Interest</title>
          <p>Progression and occurrence of in-hospital outcomes were assessed during hospitalization and, subsequently, via telephone contact and review of medical records. The primary outcome was defined as the occurrence of: (1) death from cardiovascular causes; (2) reinfarction, defined as recurrent ischemic pain (although not mandatory), new ST-segment elevation &#8805; 0.1 mV or new Q wave in at least two contiguous leads or abnormal (above the upper limit of normal according to the reference range used by the local laboratory or at least 50% above the value in the previous test) levels of serum markers (troponin or creatine kinase-MB); or (3) recurrent angina, defined as persistent pain, need for sublingual nitrate, or readmission due to recurrent angina.</p>
          <p>The secondary outcome was a composite of: (1) stroke; (2) nonfatal cardiac arrest; (3) major bleeding (defined as the need for blood transfusion due to a drop of more than 3 g/dL in the hemoglobin test, and/or hemoglobin level below 10 g/dL, and/or hemodynamic instability, and/or prolonged hospitalization due to major bleeding, and/or hemorrhagic stroke; or (4) need for unplanned percutaneous or surgical reintervention.</p>
        </sec>
        <sec>
          <title>Statistical Analysis</title>
          <p>Statistical analysis was performed using IBM SPSS Statistics version 22.0 for Windows. Age and time between primary PCI and new procedure were described as mean &#177; standard deviation. Categorical variables were described as absolute and relative frequency. The distributions of numerical variables were compared between the CR and culprit-artery-only groups using analysis of variance with a single criterion of classification, while those of categorical variables were compared using Pearson&#8217;s chi-square test with continuity correction or Fisher&#8217;s exact test whenever appropriate. The chance of primary outcome, secondary outcome, and death from all causes occurring were compared between the groups described above using binary logistic regression. In multivariable analysis, models were compared using the likelihood ratio test. Kaplan-Meier curves for STEMI were calculated for CR and IR. Differences in survival rate were assessed by the log-rank test. Odds ratios were described with their respective 95% confidence intervals. Tests with p-value &lt; 0.05 were considered statistically significant. (Seria cardiovascular causes?)</p>
        </sec>
      </sec>
      <sec sec-type="results">
        <title>Results</title>
        <p>From January 2015 to March 2016, 248 patients with a diagnosis of STEMI were admitted to the emergency departments at the two study centers; of those, 85 (34.3%) patients had multivessel CAD.</p>
        <p>Of the total 85 patients, 58 (68.2%) were treated with CR and 27 (31.8%) were treated with culprit-artery-only revascularization. The mean age was 62&#177;12 years, and 61 (71.8%) participants were male. Inferior infarction occurred in 42 (49.4%) patients, followed by anterior infarction in 37 (43.5%). Seventy-one (83.5%) patients were rated as Killip class I at admission, and 68 (78.8%) had double-vessel disease. The LAD was responsible for 32 (37.6%) infarctions, while the lesion was found to be related to the acute myocardial infarction in 36 (42.4%) patients. Finally, 17 (20.0%) patients had no significant lesions in that artery, as described in <xref ref-type="table" rid="t1001">Table 1</xref> . There was no statistically significant difference between the two revascularization strategies in any of the characteristics that were analyzed, including door-to-balloon time.</p>
        <p>
          <table-wrap id="t1001">
            <label>Table 1</label>
            <caption>
              <title>&#8211; Clinical and demographic characteristics of the study population (n = 85)</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="20%">
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <thead>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th align="left" style="font-weight:normal"> </th>
                  <th colspan="2">Revascularization strategy</th>
                  <th align="left" style="font-weight:normal"> </th>
                </tr>
                <tr>
                  <th align="left" style="font-weight:normal"> </th>
                  <th>Overall</th>
                  <th>Complete</th>
                  <th>Incomplete</th>
                  <th>p</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td>
                    <bold>Center</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0.43</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>1</italic>
                  </td>
                  <td align="center">28 (32.9%)</td>
                  <td align="center">17 (60.7%)</td>
                  <td align="center">11 (39.3%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>2</italic>
                  </td>
                  <td align="center">57 (67.1%)</td>
                  <td align="center">41 (71.9%)</td>
                  <td align="center">16 (28.1%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td><bold>Age</bold> (years)</td>
                  <td align="center">62&#177;12</td>
                  <td align="center">62.7&#177;12</td>
                  <td align="center">60.6&#177;13</td>
                  <td align="center">0.46</td>
                </tr>
                <tr>
                  <td>
                    <bold>Male</bold>
                  </td>
                  <td align="center">61 (71.8%)</td>
                  <td align="center">42 (72.4%)</td>
                  <td align="center">19 (74.0%)</td>
                  <td align="center">0.99</td>
                </tr>
                <tr>
                  <td>
                    <bold>White</bold>
                  </td>
                  <td align="center">80 (94.1%)</td>
                  <td align="center">55 (94.8%)</td>
                  <td align="center">25 (92.6%)</td>
                  <td align="center">0.99</td>
                </tr>
                <tr>
                  <td>
                    <bold>Previous history</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Hypertension</italic>
                  </td>
                  <td align="center">54 (63.5%)</td>
                  <td align="center">37 (63.8%)</td>
                  <td align="center">17 (63.0%)</td>
                  <td align="center">0.99</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Diabetes</italic>
                  </td>
                  <td align="center">22 (25.9%)</td>
                  <td align="center">14 (24.1%)</td>
                  <td align="center">8 (29.6%)</td>
                  <td align="center">0.79</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Smoking</italic>
                  </td>
                  <td align="center">26 (30.6%)</td>
                  <td align="center">21 (36.2%)</td>
                  <td align="center">5 (18.5%)</td>
                  <td align="center">0.16</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Previous CAD</italic>
                  </td>
                  <td align="center">10 (11.8%)</td>
                  <td align="center">5 (8.6%)</td>
                  <td align="center">5 (18.5%)</td>
                  <td align="center">0.34</td>
                </tr>
                <tr>
                  <td>
                    <bold>AMI location</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0.94*</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Anterior</italic>
                  </td>
                  <td align="center">37 (43.5%)</td>
                  <td align="center">26 (44.8%)</td>
                  <td align="center">11 (40.7%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Inferior</italic>
                  </td>
                  <td align="center">42 (49.4%)</td>
                  <td align="center">28 (48.3%)</td>
                  <td align="center">14 (51.9%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Lateral</italic>
                  </td>
                  <td align="center">6 (7.1%)</td>
                  <td align="center">4 (6.9%)</td>
                  <td align="center">2 (7.4%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td>
                    <bold>LBBB</bold>
                  </td>
                  <td align="center">4 (4.7%)</td>
                  <td align="center">2 (3.4%)</td>
                  <td align="center">2 (7.4%)</td>
                  <td align="center">0.80*</td>
                </tr>
                <tr>
                  <td>
                    <bold>No. of stenoses</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0.87</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>2</italic>
                  </td>
                  <td align="center">67 (78.8%)</td>
                  <td align="center">46 (79.3%)</td>
                  <td align="center">21 (77.8%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>3</italic>
                  </td>
                  <td align="center">18 (21.1%)</td>
                  <td align="center">12 (20.7%)</td>
                  <td align="center">6 (22.2%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td>
                    <bold>LAD</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0.28</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Culprit</italic>
                  </td>
                  <td align="center">32 (37.6%)</td>
                  <td align="center">22 (37.9%)</td>
                  <td align="center">10 (37.0%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>Nonculprit</italic>
                  </td>
                  <td align="center">36 (42.4%)</td>
                  <td align="center">27 (46.6%)</td>
                  <td align="center">9 (33.3%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>No lesion</italic>
                  </td>
                  <td align="center">17 (20.0%)</td>
                  <td align="center">9 (15.5%)</td>
                  <td align="center">8 (29.6%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td>
                    <bold>LVEF &lt; 50%</bold>
                  </td>
                  <td align="center">41 (48.2%)</td>
                  <td align="center">25 (43.1%)</td>
                  <td align="center">16 (59.3%)</td>
                  <td align="center">0.25</td>
                </tr>
                <tr>
                  <td>
                    <bold>Killip class</bold>
                  </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td align="center">0.62*</td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>1</italic>
                  </td>
                  <td align="center">71 (83.5%)</td>
                  <td align="center">50 (86.2%)</td>
                  <td align="center">21 (77.8%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>2</italic>
                  </td>
                  <td align="center">7 (8.2%)</td>
                  <td align="center">4 (6.9%)</td>
                  <td align="center">3 (11.1%)</td>
                  <td> </td>
                </tr>
                <tr>
                  <td align="right">
                    <italic>3</italic>
                  </td>
                  <td align="center">7 (8.2%)</td>
                  <td align="center">4 (6.9%)</td>
                  <td align="center">3 (11.1%)</td>
                  <td> </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="TFN1001">
                <p>
                  <italic>Values are mean &#177; standard deviation or absolute and relative frequency. p: probability value; analysis of variance was used for age; for the others, Pearson&#8217;s chi-square text or *Fischer&#8217;s exact test was used. CAD: coronary artery disease; AMI: acute myocardial infarction; LBBB: left bundle branch block; LAD: left anterior descending artery; LVEF: left ventricular ejection fraction.</italic>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <sec>
          <title>Coronary Intervention</title>
          <p>Of the 58 patients who were given the CR strategy, 6 (10.3%) were fully treated at the index event &#8211; all of them had double-vessel disease, including four patients with the diagonal branch and two patients with the LAD as the nonculprit artery that was treated. Fifty-two patients were treated with staged revascularization of the nonculprit artery &#8211; 38 at the initial admission and 14 at a subsequent admission. The mean time between primary PCI and the new procedure was 13&#177;11 days, ranging from 3 to 40 days. Detailed treatment (including PCI and drug therapy) is described in <xref ref-type="table" rid="t2001">Table 2</xref> .</p>
          <p>
            <table-wrap id="t2001">
              <label>Table 2</label>
              <caption>
                <title>&#8211; Coronary intervention and drug therapy (n = 85)</title>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup width="20%">
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" style="font-weight:normal"> </th>
                    <th align="left" style="font-weight:normal"> </th>
                    <th colspan="2">Revascularization strategy</th>
                    <th align="left" style="font-weight:normal"> </th>
                  </tr>
                  <tr>
                    <th align="left" style="font-weight:normal"> </th>
                    <th>Overall</th>
                    <th>Complete</th>
                    <th>Incomplete</th>
                    <th>p</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>
                      <bold>Previous thrombolytic therapy</bold>
                    </td>
                    <td align="center">3 (3.5%)</td>
                    <td align="center">3 (5.2%)</td>
                    <td align="center">0</td>
                    <td align="center">0.57*</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Stent type</bold>
                    </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td align="center">0.30*</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Bare-metal</italic>
                    </td>
                    <td align="center">76 (89.4%)</td>
                    <td align="center">50 (86.2%)</td>
                    <td align="center">26 (96.3%)</td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Drug-eluting</italic>
                    </td>
                    <td align="center">9 (10.6%)</td>
                    <td align="center">8 (13.8%)</td>
                    <td align="center">1 (3.7%)</td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Glycoprotein IIb/IIIa inhibitors</bold>
                    </td>
                    <td align="center">23 (27.1%)</td>
                    <td align="center">14 (24.1%)</td>
                    <td align="center">9 (33.3%)</td>
                    <td align="center">0.53</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Medical therapy within 24 h</bold>
                    </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>ASA</italic>
                    </td>
                    <td align="center">85 (100%)</td>
                    <td align="center">58 (100%)</td>
                    <td align="center">27 (100%)</td>
                    <td align="center">-</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Clopidogrel</italic>
                    </td>
                    <td align="center">85 (100%)</td>
                    <td align="center">58 (100%)</td>
                    <td align="center">27 (100%)</td>
                    <td align="center">-</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Statin</italic>
                    </td>
                    <td align="center">85 (100%)</td>
                    <td align="center">58 (100%)</td>
                    <td align="center">27 (100%)</td>
                    <td align="center">-</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Beta-blocker</italic>
                    </td>
                    <td align="center">43 (50.6%)</td>
                    <td align="center">26 (44.8%)</td>
                    <td align="center">17 (63.0%)</td>
                    <td align="center">0.19</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>ACEI/ARB</italic>
                    </td>
                    <td align="center">40 (47.1%)</td>
                    <td align="center">27 (46.6%)</td>
                    <td align="center">13 (48.1%)</td>
                    <td align="center">0.99</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Nitrate</italic>
                    </td>
                    <td align="center">30 (35.3%)</td>
                    <td align="center">20 (34.5%)</td>
                    <td align="center">10 (37.0%)</td>
                    <td align="center">0.99</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>SYNTAX score</bold>
                    </td>
                    <td> </td>
                    <td> </td>
                    <td> </td>
                    <td align="center">0.34*</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Low</italic>
                    </td>
                    <td align="center">41 (48.2%)</td>
                    <td align="center">30 (51.7%)</td>
                    <td align="center">11 (40.7%)</td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Moderate</italic>
                    </td>
                    <td align="center">44 (51.8%)</td>
                    <td align="center">28 (48.3%)</td>
                    <td align="center">16 (59.3%)</td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>High</italic>
                    </td>
                    <td align="center">&#8212;</td>
                    <td align="center">&#8212;</td>
                    <td align="center">&#8212;</td>
                    <td> </td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN2001">
                  <p>
                    <italic>Values are absolute and relative frequency. p: probability value; analysis of variance was used for age; for the others, Pearson&#8217;s chi-square text or *Fischer&#8217;s exact test was used. ASA: acetylsalicylic acid; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.</italic>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>Bare-metal stents were implanted in 76 (89.4%) patients. All patients were given dual antiplatelet therapy and statin within 24 hours. Glycoprotein IIb/IIIa inhibitor was used in 23 (27.1%) patients. Regarding the SYNTAX score, 41 (48.2%) patients had a low score, while 44 (51.8%) had a moderate score. No patient had a high SYNTAX score, and there was no statistically significant difference between the two revascularization strategies regarding the distribution of the scores.</p>
        </sec>
        <sec>
          <title>Clinical Outcomes</title>
          <p>Overall mortality was 8.2%, and 86% of deaths occurred in hospital. The chance of both the primary and secondary outcomes occurring was significantly greater among individuals treated with IR when compared to those treated with CR (OR 5.1, 95% CI 1.6-16.1 vs. OR 5.2, 95% CI 1.2-22.9, respectively). If the chance of cardiac death is analyzed separately, the result was similar (OR 6.4, 95% CI 1.2-35.3), as described in <xref ref-type="table" rid="t3001">Table 3</xref> . Deaths occurred predominantly in hospital, and only one patient died in the late stage of the IR strategy.</p>
          <p>
            <table-wrap id="t3001">
              <label>Table 3</label>
              <caption>
                <title>&#8211; Clinical outcomes according to revascularization strategy (n = 85)</title>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup width="20%">
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" style="font-weight:normal"> </th>
                    <th align="left" style="font-weight:normal"> </th>
                    <th colspan="2">Revascularization strategy</th>
                    <th align="left" style="font-weight:normal"> </th>
                  </tr>
                  <tr>
                    <th align="left" style="font-weight:normal"> </th>
                    <th style="font-weight:normal">Complete n (%)</th>
                    <th style="font-weight:normal">Incomplete n (%)</th>
                    <th style="font-weight:normal">OR (95% CI)</th>
                    <th>p</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>
                      <bold>Primary outcome (composite)</bold>
                    </td>
                    <td align="center">6 (10.3%)</td>
                    <td align="center">10 (37.0%)</td>
                    <td align="center">5.10 (1.6-16.1)</td>
                    <td align="center">0.005</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Cardiac death</italic>
                    </td>
                    <td align="center">2 (3.4%)</td>
                    <td align="center">5 (18,5%)</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Reinfarction</italic>
                    </td>
                    <td align="center">&#8212;</td>
                    <td align="center">&#8212;</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Angina</italic>
                    </td>
                    <td align="center">4 (6.9%)</td>
                    <td align="center">5 (18.5%)</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Secondary outcome (composite)</bold>
                    </td>
                    <td align="center">3 (5.17%)</td>
                    <td align="center">6 (22.2%)</td>
                    <td align="center">5.24 (1.2-22.9)</td>
                    <td align="center">0.022</td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Stroke</italic>
                    </td>
                    <td align="center">&#8212;</td>
                    <td align="center">&#8212;</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Nonfatal cardiac arrest</italic>
                    </td>
                    <td align="center">2 (3.4%)</td>
                    <td align="center">&#8212;</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Major bleeding</italic>
                    </td>
                    <td align="center">1 (1.7%)</td>
                    <td align="center">&#8212;</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                  <tr>
                    <td align="right">
                      <italic>Reintervention</italic>
                    </td>
                    <td align="center">&#8212;</td>
                    <td align="center">6 (22.2%)</td>
                    <td> </td>
                    <td> </td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN3001">
                  <p>
                    <italic>OR: odds ratio; CI: confidence interval.</italic>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>In multivariate analysis, as described in <xref ref-type="table" rid="t4001">Table 4</xref> , CR was associated with a decreased chance of both primary and secondary outcomes occurring regardless of sex, age, diabetes, culprit lesion in the LAD, and presence of LAD lesion and ejection fraction &lt; 50%. Also, CR was associated with a decreased chance of the primary outcome occurring regardless of the ventricular wall affected and the extent of CAD. The Kaplan-Meier curves showed a decreased 12-month survival in patients with multivessel disease post-STEMI who underwent IR (p = 0.017) ( <xref ref-type="fig" rid="f01001">Figure 1</xref> ).</p>
          <p>
            <table-wrap id="t4001">
              <label>Table 4</label>
              <caption>
                <title>&#8211; Independent association between staged revascularization strategy and incidence of primary and secondary outcomes in a 1-year follow-up (n = 85)</title>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup width="33%">
                  <col/>
                  <col/>
                  <col/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" style="font-weight:normal"> </th>
                    <th style="font-weight:normal">Primary outcome* OR (95% CI)</th>
                    <th style="font-weight:normal">Secondary outcome<sup>&#8224;</sup>OR (95% CI)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>
                      <bold>Unadjusted</bold>
                    </td>
                    <td align="center">5.1 (1.6-16.1)</td>
                    <td align="center">5.2 (1.2-22.9)</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Model 2</bold>
                      <sup>
                        <bold>&#8225;</bold>
                      </sup>
                    </td>
                    <td align="center">5.2 (1.6-16.5)</td>
                    <td align="center">5.1 (1.1-23.0)</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Model 3</bold>
                      <sup>
                        <bold>&#167;</bold>
                      </sup>
                    </td>
                    <td align="center">5.1 (1.6-16.4)</td>
                    <td align="center">4.9 (1.1-23.1)</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Model 4</bold>
                      <sup>
                        <bold>//</bold>
                      </sup>
                    </td>
                    <td align="center">5.1 (1.6-16.4)</td>
                    <td align="center">5.1 (1.1-24.1)</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Model 5</bold>
                      <sup>
                        <bold>&#182;</bold>
                      </sup>
                    </td>
                    <td align="center">5.1 (1.6-16.7)</td>
                    <td align="center">4.3 (0.9-21.0)</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Model 6</bold>
                      <sup>
                        <bold>#</bold>
                      </sup>
                    </td>
                    <td align="center">4.6 (1.4-15.3)</td>
                    <td align="center">3.6 (0.7-19.6)</td>
                  </tr>
                  <tr>
                    <td>
                      <bold>Model 7**</bold>
                    </td>
                    <td align="center">4.7 (1.4-15.7)</td>
                    <td align="center">2.3 (0.4-14.2)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN4001">
                  <p>
                    <italic>OR: odds ratio; CI: confidence interval. *Death, reinfarction, angina;<sup>&#8224;</sup>Stroke, nonfatal cardiac arrest, major bleeding, reintervention.<sup>&#8225;</sup>Adjusted for age and sex.<sup>&#167;</sup>Model 2 + adjustment for diabetes.<sup>//</sup>Model 3 + adjustment for culprit lesion in left anterior descending artery (LAD).<sup>&#182;</sup>Model 4 + LAD lesion and ejection fraction &lt; 50%.<sup>#</sup>Model 5 + infarction location. **Model 6 + number of lesions.</italic>
                  </p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </p>
          <p>
            <fig id="f01001">
              <label>Figure 1</label>
              <caption>
                <title>&#8211; <italic>Twelve-month survival after complete revascularization (CR) and incomplete revascularization (IR) in patients with acute ST-segment elevation myocardial infarction (STEMI) and multivessel disease. *Log-rank test.</italic></title>
              </caption>
              <graphic xlink:href="1678-4170-abc-115-02-0229-80346-gf01-en.tif"/></fig>
          </p>
        </sec>
      </sec>
      <sec sec-type="discussion">
        <title>Discussion</title>
        <p>In this real-world practice registry, we showed that the CR strategy is associated with a significant reduction in hard outcomes in a 1-year follow-up when compared to the IR strategy. Also, the treatment of nonculprit arteries during primary PCI was uncommon, as most patients with multivessel CAD and STEMI were managed with a staged approach within 40 days of the index event.</p>
        <p>Multivessel CAD occurs in approximately 40-50% of patients with STEMI<sup><xref ref-type="bibr" rid="B3">3</xref> - <xref ref-type="bibr" rid="B4">4</xref></sup> and is considered a strong independent predictor of mortality.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> In our study population, the prevalence was about 35%. The natural history of STEMI demonstrates that the occurrence of more generalized pathophysiological derangements has the potential to compromise coronary perfusion beyond the culprit artery distribution and destabilize plaque throughout the coronary vascular bed.<sup><xref ref-type="bibr" rid="B13">13</xref></sup> The pathological process of STEMI involves the entire coronary tree, and the dynamics of this specific inflammatory process is greater in the first month following the acute event,<sup><xref ref-type="bibr" rid="B14">14</xref></sup> which may explain an increased mortality rate within 30 days,<sup><xref ref-type="bibr" rid="B15">15</xref></sup> as seen in the present study. Because these patients have poor prognosis, the role of CR within the context of STEMI should be examined considering the impact of the aforementioned factors on determining whether an aggressive strategy could provide clinical benefit.<sup><xref ref-type="bibr" rid="B13">13</xref></sup></p>
        <p>Consistent with the still conservative recommendations of contemporary guidelines for real-world clinical practice, several registries demonstrate that the use of multivessel approach ranges from 9% to 24.4%.<sup><xref ref-type="bibr" rid="B16">16</xref> - <xref ref-type="bibr" rid="B18">18</xref></sup> In the ProACS (Portuguese Registry of Acute Coronary Syndromes) registry, for example, the rate was 19.2%. In our study, the approach was used in 68.2%. According to some authors, discrepancy between current guidelines and clinical practice results from several factors, including lack of clinical evidence and economic issues involving paying sources and current protocols. The subject is controversial and will only be resolved with a broad international study.<sup><xref ref-type="bibr" rid="B19">19</xref></sup> Within the context of multivessel treatment, our study showed a predominance of patients with double-vessel disease (78.8%), in agreement with studies such as the PRAMI trial,<sup><xref ref-type="bibr" rid="B7">7</xref></sup> and patients with less complex lesions, as there were no participants with a high SYNTAX score. Those findings suggest that more severe patients &#8211; with triple-vessel disease and a high SYNTAX score &#8211; had indication for surgical treatment following primary angioplasty at the study centers.</p>
        <p>With regard to drug therapy, all patients were given dual antiplatelet therapy and statins as recommended in STEMI guidelines. There was no difference in the use of glycoprotein IIb/IIIa inhibitors between the groups (around 27.1%), although a large metanalysis concluded that greater benefits are observed in high-risk patients, such as those undergoing CR.<sup><xref ref-type="bibr" rid="B20">20</xref></sup> Another highlight is the high rate of bare-metal stenting (89.4%), which differs from the results of randomized clinical trials (RCTs).<sup><xref ref-type="bibr" rid="B7">7</xref> - <xref ref-type="bibr" rid="B10">10</xref></sup> This shows a disparity between patients included in RCTs and real-world patients, which reinforces the importance of population registries. Although RCTs use the most widely accepted design for comparing treatments, they have left many important questions unanswered. Careful review of clinical registry information is believed to provide a complementary approach to RCTs, especially because of the potential inclusion of more representative samples of the target population. Furthermore, as RCTs are conducted at centers of excellence, it remains unclear whether their results can be generalized to usual clinical practice. The operator&#8217;s experience, for example, varies across institutions and may interfere with the results. Registries such as the present study show that even in suboptimal conditions the benefit of CR in patients with multivessel disease remains significant.<sup><xref ref-type="bibr" rid="B21">21</xref></sup> The SCAAR (Swedish Coronary Angiography and Angioplasty Registry) study followed up from 2006 to 2010 a total of 23,342 patients with multivessel disease who underwent coronary angioplasty with IR and assessed its long-term association with death, new intervention, and myocardial infarction. IR at the time of hospital discharge was associated with a high risk of adverse cardiac events within 1 year, with an adjusted hazard ratio of death and the combination of death/infarction of 1.29 (95% CI 1.12-1.49; p = 0.0005) and 1.42 (95% CI 1.30-1.56; p &lt; 0.0001), respectively.</p>
        <p>This study was able to demonstrate a significant benefit of CR in reducing mortality, even when a staged approach was used. CR at the index event was uncommon, being performed only in patients with double-vessel disease, favorable anatomy, and lower severity at admission (Killip class I). Another important finding was the significant benefit regarding repeat revascularization and recurrent angina. In patients with STEMI treated with primary PCI at real-world hospital settings, CR does not increase short- and long-term mortality, proving to be safe when a staged approach is used.<sup><xref ref-type="bibr" rid="B22">22</xref></sup></p>
        <p>Although the benefit of a staged strategy following primary PCI has been suggested in several studies including this one, questions remain to be elucidated, such as appropriate timing for staged PCI. In clinical practice, factors such as renal dysfunction, lesion complexity, contrast volume, radiation dose, hemodynamic status, and patient status may influence the decision on optimal timing for revascularization. An electronic survey conducted by the ACC revealed that, although most interventional cardiologists agree to perform CR with a staged approach, their opinions regarding optimal timing for the second PCI vary greatly. Only 22% of respondents performed both first and second interventions at the same hospitalization; most cardiologists recommended waiting at least 15 days for the second procedure.<sup><xref ref-type="bibr" rid="B23">23</xref></sup></p>
        <p>Despite the evidence and ongoing studies, no study may be able to define a single strategy for patients with STEMI and multivessel CAD. As these patients are heterogeneous, the strategy must be individualized. Undoubtedly, the focus should be on treating the culprit lesion. The decision should ideally be made by a heart team taking anatomical complexity, ventricular function, and patient profile into account in order to reach the best strategy. A complete risk stratification with clinical and angiographic data is crucial for evaluating the patients properly.<sup><xref ref-type="bibr" rid="B24">24</xref></sup></p>
        <p>The present study has some limitations that should be considered, especially those related to its observational nature. The chance of selection bias cannot be excluded, even though no statistically significant differences were identified regarding the study variables related to the baseline characteristics of patients treated with CR or IR. Also, no change was found in the effect of the strategy on the occurrence of primary outcome due to the factors considered in multivariable analysis, as the intervention strategy was at the operator&#8217;s discretion. Moreover, this study included a small number of patients from two centers in southern Brazil and may not be representative of settings in other regions and non-public services.</p>
      </sec>
      <sec sec-type="conclusions">
        <title>Conclusions</title>
        <p>In the present study, we used real-world data from clinical practice at two centers in southern Brazil and found that, in patients with multivessel CAD within the context of STEMI undergoing primary PCI, the CR strategy is associated with a significant reduction in primary and secondary outcomes in a 1-year follow-up when compared to the IR strategy. These data should prompt discussion about current clinical and institutional protocols.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn fn-type="other">
          <p>Study Association</p>
          <p>This article is part of the thesis of master submitted by Julia Cremona Cadore, from Universidade Federal do Rio Grande do Sul.</p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="supported-by">
          <p>Sources of Funding</p>
          <p>There was no external funding source for this study.</p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="other">
          <label>ERRATUM</label>
          <p>
            <bold>August 2020 Issue, vol. 115 (2), pages 229-237</bold>
          </p>
          <p>In the Original Article &#8220;Complete Revascularization Versus Treatment of the Culprit Artery Only in ST Elevation Myocardial Infarction: A Multicenter Registry&#8221;, with DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.36660/abc.20180346">https://doi.org/10.36660/abc.20180346</ext-link>, published in the periodical Arquivos Brasileiros de Cardiologia, 115(2):229-237, on page 229, correct author name Alexandre Tognon to: Alexandre Pereira Tognon and the author Rog&#233;rio Tumelero to: Rog&#233;rio Tadeu Tumelero. Remove the institution: Universidade de Passo Fundo, Passo Fundo, RS - Brazil and change to: Associa&#231;&#227;o Hospitalar Beneficente S&#227;o Vicente de Paulo, Passo Fundo, RS - Brazil from the affiliations of the authors Alexandre Pereira Tognon and Rog&#233;rio Tadeu Tumelero.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
